Stockwinners Market Radar for September 05, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:13 EDT Cathie Wood's ARK Investment sold 217.5K shares of Shopify today

18:32 EDT Honest Company affirms FY23 guidance - As part of its press release naming new CFO, the company states: "The Company anticipates a seamless transition and re-affirms its full year revenue and adjusted EBITDA outlook communicated in its August 8, 2023 second quarter earnings release."

18:27 EDT Microsoft exec sells $8.78M in common stock - In a regulatory filing, Microsoft disclosed that its HR EVP Kathleen Hogan sold 26.8K shares of common stock on September 1st in a total transaction size of $8.78M.

18:07 EDT Harmony Biosciences receives FDA orphan drug designation for pitolisant - Harmony Biosciences announced that the FDA has granted Orphan Drug Designation designation for pitolisant for the treatment of idiopathic hypersomnia. Reference Link

17:34 EDT Veritex Community Bank appoints Dominic Karaba as Chief Banking Officer - Veritex Holdings, the holding company for Veritex Community Bank, announced, following an extensive nationwide search by Chartwell Partners, the hiring of Dominic Karaba as President and Chief Banking Officer of Veritex Community Bank effective September 18. Karaba has more than 28 years of experience in the banking industry and most recently served as UMB Financial Corporation's President of Commercial Banking. He has a bachelor's degree in business from the University of Puget Sound and a graduate degree in banking and bank leadership from the Pacific Coast Graduate School of Banking. As President of the Bank, he will oversee all revenue lines of business, as well as strategic revenue initiatives, with the goal of driving sustainable growth. Karaba will report directly to C. Malcolm Holland, III, who will remain CEO and Chairman of the Board of Veritex Community Bank as well as President, CEO and Chairman of the Board of Veritex Holdings.

17:28 EDT GAP Airports reports August traffic up 14.1% year-over-year - Grupo Aeroportuario del Pacifico announces preliminary terminal passenger traffic figures for the month of August 2023, compared with the same period of 2022. For August 2023, the total number of terminal passengers at GAP's 12 Mexican airports increased by 14.3%, compared to the same period in 2022. Guadalajara, Tijuana, Los Cabos, and Puerto Vallarta presented an increase in passenger traffic of 18.0%, 11.7%, 5.2%, and 0.7% respectively, compared to August 2022. On the other hand, Montego Bay increased by 15.5%, compared to 2022. The number of seats available during August 2023 increased by 10.7%, compared to August 2022; load factors for the month went from 78.9% in August 2022 to 81.4% in August 2023.

17:04 EDT Mobiv Acquisition extends time available to consummate business combination - Mobiv Acquisition announced that, on September 5 it notified the trustee of the Company's trust account that it was extending the time available to the Company to consummate an initial business combination from September 8 to October 8. The Extension is the fifth of up to nine one-month extensions permitted under the Company's governing documents. In connection with such Extension, Mobiv Pte. deposited an aggregate of $100,000.00 into the Company's trust account on September 5, on behalf of the Company.

16:52 EDT Darling Ingredients CEO sells $6.24M in common stock - In a regulatory filing, Darling Ingredients disclosed that its CEO Randall Stuewe sold 100K shares of common stock on September 1st in a total transaction size of $6.24M.

16:48 EDT Enbridge down 7% at $32.79 after announcing $14B asset purchase from Dominion

16:36 EDT GitLab jumps 7% to $53.30 after Q2 earnings beat, FY24 guidance raise

16:33 EDT Abbott to acquire Bigfoot for undisclosed amount - Abbott and Bigfoot Biomedical announced a definitive agreement for Abbott to acquire Bigfoot, a leader in developing smart insulin management systems for people with diabetes. The transaction is subject to customary closing conditions and is expected to close in the Q3. Financial terms were not disclosed. Abbott and Bigfoot have worked together on connected diabetes solutions since 2017. Bigfoot developed Bigfoot Unity, a smart insulin management system that features the first and only FDA-cleared connected insulin pen caps that use integrated continuous glucose monitoring data along with healthcare provider instructions to provide insulin dosing recommendations.

16:30 EDT Civeo initiates regular dividend of 25c per share - The cash dividend is payable on September 29, 2023 to shareholders of record as of close of business on September 15, 2023.

16:25 EDT Ascendis: eGFR improved in TransCon PTH-treated adults with hypoparathyroidism - Ascendis Pharma announced new post hoc analysis showing adults with hypoparathyroidism treated with TransCon PTH demonstrated substantial improvement in estimated glomerular filtration rate, eGFR , suggesting improved kidney function. TransCon PTH, palopegteriparatid, is an investigational prodrug of parath yroid hormone PTH 1-34 administered once daily designed to provide sustained release of active PTH within the physiological range for 24 hours per day in adult patients with hypoparathyroidism. "Chronic kidney disease is one of the most consequential complications of chronic hypoparathyroidism and its treatment with conventional therapy. Diminished kidney function is associated with its own set of complications, including hypertension, edema, and weakness," said Dr. Aliya Khan, M.D., Clinical Professor of Medicine at McMaster University and Director of the Calcium Disorders Clinic at McMaster University Medical Center. "The observations in the post hoc analysis of the PaTHway Trial, suggesting that treatment with TransCon PTH reverses impaired kidney function in patients with hypoparathyroidism, further substantiating the promise for a major improvement in treatment opportunities and outcomes for people living with hypoparathyroidism.""We will continue to study this important data and topic, which suggests the potential of TransCon PTH to address physician and patient concerns about soft-tissue calcifications and decreased kidney function associated with conventional therapy," said Aimee Shu, M.D., Vice President, Clinical Development, Endocrine & Rare Diseases at Ascendis Pharma. "In addition to reducing risk for patients, this could also help significantly reduce the healthcare burden associated with hypoparathyroidism. We look forward to presenting detailed results at an upcoming medical conference.""We will continue to study this important data and topic, which suggests the potential of TransCon PTH to address physician and patient concerns about soft-tissue calcifications and decreased kidney function associated with conventional therapy," said Aimee Shu, M.D., Vice President, Clinical Development, Endocrine & Rare Diseases at Ascendis Pharma. "In addition to reducing risk for patients, this could also help significantly reduce the healthcare burden associated with hypoparathyroidism. We look forward to presenting detailed results at an upcoming medical conference."

16:22 EDT Netflix co-CEO Greg Peters says top priority is scale - Says had top TV series in 27 of 28 weeks in recent Nielsen data. Says ultimately want to engineer way to a place where company is agnostic to whether users are mostly ad-tier or ad-free tier. Comments taken from the Goldman Sachs Communacopia + Technology Conference.

16:19 EDT Dominion sells natural gas distribution companies to Enbridge for $14B - Dominion Energy (D) announced that it has concluded a robust and competitive sale process and executed three separate definitive agreements to sell its three natural gas distribution companies to Enbridge (ENB). The three LDCs - The East Ohio Gas Company, Public Service Company of North Carolina, Incorporated, and Questar Gas Company along with Wexpro Company - serve about 3M homes and businesses in Ohio, North Carolina, Utah, Wyoming, and Idaho and collectively comprise approximately 78,000 miles of natural gas distribution, transmission, gathering, and storage pipelines; more than 62 Bcf of working underground and liquefied natural gas storage capacity; and approximately 400 Bcfe of cost-of-service regulated gas reserves as of year-end 2022. Aggregate transactions value of $14.0B , including the assumption of $4.6B of debt, represents approximately 1.5x estimated 2022 year-end rate base of $9.2B. Aggregate purchase price of $9.4B represents approximately 16.6x estimated 2023 operating earnings of $564M and approximately 16.7x estimated 2024 operating earnings of $561M. Total estimated after-tax proceeds of $8.7B are expected to be used to reduce parent debt in addition to the conveyance of $4.6B of operating company debt. The transactions are expected to improve the company's consolidated FFO to debt by approximately 3.4%. The transactions require clearance under the Hart-Scott-Rodino Act, approval from the Federal Communications Commission, approval from the Committee on Foreign Investment in the United States as well as review or approval from Idaho Public Utilities Commission, North Carolina Utilities Commission, Public Utilities Commission of Ohio, Utah Public Service Commission, and Wyoming Public Service Commission. Closing of each transaction is expected to occur following receipt of each respective state regulatory approval, as required, and are not cross conditioned upon each other. The assets included in the transactions will be reclassified as discontinued operations for GAAP reporting and excluded from operating earnings for the Q3 and FY23. The company said, "We expect a decrease of 5c-6c per share from the previously announced Q3 operating earnings guidance range of 72c-87c per share for the removal of such assets, which excludes any potential impact from the use of sales proceeds. Given the pending business review, the company has not provided FY23 earnings guidance." McGuireWoods served as legal counsel to Dominion Energy. Citi and Goldman Sachs & Co. acted as co-financial advisors for the transaction.

16:17 EDT Ascendis Pharma raises FY23 U.S. SKYTROFA revenue view to EUR165M-EUR170M -

16:12 EDT Enbridge to acquire three U.S. based utilities from Dominion Energy for $14B - Enbridge (ENB) announced that it has entered into three separate definitive agreements with Dominion Energy (D) to acquire EOG, Questar and PSNC for an aggregate purchase price of $14B, comprised of $9.4B of cash consideration and $4.6B of assumed debt, subject to customary closing adjustments. Upon the closings of the three transactions, Enbridge will add gas utility operations in Ohio, North Carolina, Utah, Idaho and Wyoming, representing a significant presence in the U.S. utility sector. The Gas utilities fit Enbridge's long held investor proposition of low-risk businesses with predictable cash flow growth and strong overall returns. Following the closings, the acquisitions will double the scale of the company's gas utility business to approximately 22% of Enbridge's total adjusted EBITDA and balance the company's asset mix evenly between natural gas and renewables, and liquids. The acquisitions will lower Enbridge's already industry-leading business risk and secure visible, low-risk, long-term rate base growth. Increased utility earnings enhance Enbridge's overall cash flow quality and further underpin the longevity of Enbridge's growing dividend profile. Following the closings of the acquisitions, Enbridge's gas utility business will be the largest, by volume, in North America with a combined rate base of over CDN$27B and about 7,000 employees delivering over 9 Bcf/d of gas to approximately 7M customers. The company estimates its purchase price for the acquisitions at ~1.3x Enterprise Value-to-Rate Base and ~16.5x Price-to-Earnings and expects the acquisitions to be accretive to Enbridge's financial DCFPS and adjusted EPS outlook in the first full year of ownership adding shareholder value.

16:10 EDT C4 Therapeutics CFO Lauren White to depart, Kendra Adams to succeed - C4 Therapeutics announced the appointment of Kendra Adams as chief financial officer, or CFO, effective September 18. She will succeed Lauren White, who will be leaving C4T to pursue a new role with a commercial-stage pharmaceutical company. Adams joined C4T in November 2020 as senior vice president, investor relations & corporate communications and a member of the company's management team.

16:08 EDT Mitek Systems jumps 6% to $12.00 after Q1 earnings beat, guidance raise

16:07 EDT Gogo approves $50M share repurchase program - Gogo announced that its Board of Directors approved a share repurchase program that grants the Company authority to repurchase up to $50M of shares of the Company's common stock. "Our long-term capital allocation priorities are to first maintain adequate liquidity; second, invest in high-return strategic initiatives; third, carry an appropriate level of debt with a target net leverage ratio of 2.5x - 3.5x; and fourth, return capital to shareholders," said Oakleigh Thorne, chairman and CEO. "With a strong cash balance, our Gogo 5G, Galileo and other strategic projects well-funded, our net leverage ratio at 3.0x, and with strong confidence in our business, we are now comfortable moving to priority four and returning capital to shareholders," Thorne said.

16:05 EDT Ascendis Pharma and Royalty Pharma enter into $150M royalty funding pact - Ascendis Pharma (ASND) and Royalty Pharma (RPRX) announced that Ascendis has entered into a $150M capped synthetic royalty funding agreement with Royalty Pharma based on U.S. net SKYTROFA revenue. "This transaction reflects the significant value of SKYTROFA. We are pleased to partner with Royalty Pharma, a leading funder of innovation across the biopharma industry, and look forward to partnering with them in the coming years," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "With this funding, we continue to reduce our cost of capital and provide added flexibility to support our global commercial capabilities to bring our TransCon products to patients as fast as possible." "We are excited to partner with Ascendis, a global, integrated biopharmaceutical company focused on endocrine rare disease and oncology," said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. "SKYTROFA, as the first U.S. approved weekly growth hormone therapy for pediatrics, addresses significant unmet patient need, which is underscored by its strong launch. We look forward to Ascendis' continued success in reaching as many patients as possible with this important therapy as well as the potential for label expansion in additional indications." Under the terms of the agreement, Ascendis Pharma receives an upfront payment of $150M in exchange for a 9.15% royalty on U.S. net SKYTROFA revenue, beginning on January 1, 2025. The royalty payments to Royalty Pharma will cease upon reaching a multiple of 1.925x, or 1.65x if Royalty Pharma receives royalties in that amount by December 31.

16:02 EDT Magnolia Oil & Gas to acquire certain properties in Giddings for $300M - Magnolia Oil & Gas announced that the company has entered into a definitive purchase agreement to acquire certain oil and gas producing properties including leasehold and mineral interests in Giddings for $300M, subject to customary purchase price adjustments. The cash outlay at closing is estimated to be approximately $260M, adjusted for the free cash flow generated by the assets between the effective date of July 1, 2023, and the anticipated closing date in the fourth quarter of 2023. The consideration will be funded with cash on hand, which was $677M as of June 30, 2023. The seller may also receive up to a maximum of $40M in additional contingent cash consideration through December 2025 based on future commodity prices. Magnolia President and CEO Chris Stavros stated, "We continue to leverage our accumulated knowledge and advanced understanding of Giddings by adding bolt-on oil and gas properties to expand our portfolio of high-quality opportunities and improve the overall business. Today's transaction is a natural strategic fit for Magnolia and meets both the financial and operational characteristics we look for in a bolt-on acquisition that can be easily integrated into our Giddings development program. Magnolia's acreage in Giddings now totals more than half a million net acres, with a development area of more than 150,000 net acres. Our business model is reinforced by capital discipline and provides for significant free cash flow generation through the cycle. This acquisition allows us to opportunistically deploy some of our additional cash into assets that generate high financial returns, increase our dividend per share payout capacity, and enhance value for our shareholders."

15:06 EDT Google updates Android features and renovates the Android brand - Eve Andersson, Senior Director, Product Inclusion, Equity, and Accessibility for Google blogged in part , earlier on Tuesday: "...Android is announcing a new look, as well as new features for the Google apps and devices you use every day. Here's how these updates make it easier to keep on top of tasks and stay connected on the go: The Assistant At a Glance widget uses AI to bring you helpful information like high-precision weather alerts, dynamic travel updates and upcoming event reminders on your home screen - right when you need them. On the home screen of an Android phone, the Assistant At a Glance widget is showing the current weather and upcoming flight information. Scrolling through images in a group chat, photos on your camera app or even on social media can often be inaccessible for people who are blind or low-vision. ...Lookout is also making 11 new languages available on its app, including Japanese, Korean and Chinese, bringing the total number of supported languages to 34....Easily access everyday tickets and passes in the moment you need them. With Google Wallet Pass photo import, you can digitize passes that have a barcode or a QR code, like gym or library cards." Additionally, Jason Fournier Director, Android Consumer Brand Management blogged:...moving away from our longstanding lowercase stylization of "android," we're elevating the Android logo by capitalizing the "A," adding more weight to its appearance when placed next to Google's logo. While we've added more curves and personality unique to Android, the new Android stylization more closely mirrors Google's logo and creates balance between the two." Reference Link

15:00 EDT EIP says Magellan Midstream 'better off as a stand-alone company' - Energy Income Partners, or EIP, which identifies itself as "the fourth largest and long-time shareholder in Magellan Midstream Partners," said it believes that Magellan's August 29 presentation "amounts to a series of scare tactics that present Magellan unitholders with a false choice: merge with ONEOK or else." The firm said: "EIP's decision to vote against the merger is based on the financials presented by management that show definitively that Magellan is better off as a stand-alone company, and we urge our fellow unitholders to vote 'no'." Reference Link

14:33 EDT Digital Brands Group Inc trading resumes

14:08 EDT FDIC start marketing $33B Signature Bank commercial real estate loan portfolio - The Federal Deposit Insurance Corporation, or FDIC, announced the start of a marketing process for the approximately $33B Commercial Real Estate, or CRE, loan portfolio retained in receivership following the failure of Signature Bank, New York, New York. "The majority of the CRE loan portfolio being marketed is comprised of multifamily properties, primarily located in New York City. A large portion - approximately $15B - of the CRE loans secured by multifamily residences are rent stabilized or rent controlled. The FDIC has a statutory obligation, among other factors, to maximize the preservation of the availability and affordability of residential real property for low- and moderate-income individuals. To support this obligation, the FDIC will place the rent stabilized or rent controlled loans in one or more joint ventures with the FDIC retaining a majority equity interest in the JV. In addition, the JV operating agreement will provide certain requirements that facilitate the financial and physical preservation of these loans and underlying collateral. While the FDIC will retain a majority equity interest in the JVs, the winning bidders, or partners, will act as the managing member of the joint venture and will be responsible for the management, servicing and ultimate disposition of the loans. The JV partner will be required to manage the portfolio in accordance with the JV operating agreement and be subject to stringent monitoring," the FDIC stated. Marketing of the former Signature Bank's CRE portfolio will take place over the next three months and the transactions are expected to be completed by year-end 2023. Reference Link

13:50 EDT FAA reports United Airlines cancels ground stop - A notice to the FAA's Air Traffic Control System Command Center indicates that the previous main and subs ground stop issued by United Airlines has been cancelled. Reference Link

13:21 EDT National Grid reports submission of 'Future Grid Plan' to GMAC - National Grid announced that it has submitted its Electric Sector Modernization Plan, or ESMP, which it calls "the Future Grid Plan," to the Massachusetts Grid Modernization Advisory Council, or GMAC, on Friday, September 1, "outlining the critical investments needed in the local electric distribution system over the next five years and beyond to meet the Commonwealth's nation-leading climate change, clean energy, and equity goals as established in the 2050 Clean Energy and Climate Plan." The company said: "As part of National Grid's commitment to delivering a fair, affordable, and clean energy future for all its customers, the Plan outlines a comprehensive and flexible path designed to expand and upgrade the current electric distribution grid, ensure reliability, enable increased electrification, and empower smart customer choices and the transition away from a fossil-based economy."

13:13 EDT AMD continues to see 'huge opportunity around AI' - AMD's CEO Lisa Su said during the Goldman Sachs Communocopia + Technology conference that, "We said during our last earnings call that we saw seven times more customer engagements just in the past quarter. And what that means is these are customers who are actively evaluating and using MI250s, as well as most recently MI300s, either in their labs or in our labs, and that's across a number of workloads. So, that's across training as well as inference. On the inference side, we're very advantaged because we built our MI300 family so that it could be very flexible depending on what was most important. And as a result, we have the highest memory bandwidth and memory capacity. And even since our last earnings call -- I would say over the last 30 days -- what we've seen is a continued acceleration of those engagements. And a number of those engagements have now turned into customer commitments, which we're really excited about. MI250 is an excellent product right now. So, there are a number of folks that have just started deploying and will deploy through the second half of this year. There is tremendous excitement around MI300s... We continue to see this huge opportunity around AI in datacenter."

13:01 EDT Boeing, Aviation Capital finalize order for 13 737 MAX jets - Boeing and Aviation Capital Group LLC announced the airplane lessor has finalized an order for 13 737 MAX jets, increasing the lessor's order book to 47 737 MAXs. The new, incremental order includes seven 737-8 and six 737-10 jets as ACG grows its single-aisle options to meet robust customer demand for the fuel-efficient 737 MAX airplane family. "We are pleased to expand ACG's commitment to the 737 MAX program. This additional order will allow ACG to offer highly fuel efficient and versatile aircraft to our airline customers worldwide," said Steven Udvar-Hazy, senior vice president and chief of Aircraft Operations at ACG.

12:34 EDT Microsoft, G42 announce joint sovereign cloud and AI offering - G42 and Microsoft announced that they have embarked on the next phase of their ongoing strategic collaboration with a plan to make available sovereign cloud offerings, co-innovate and deliver advanced AI capabilities, and expand the existing data center infrastructure in the UAE. Judson Althoff, Executive Vice President and Chief Commercial Officer at Microsoft, said "Microsoft's partnership with G42 will empower customers across the public sector with next-generation AI solutions built on the most trusted, comprehensive, and integrated cloud platform. With data privacy, security, and compliance as our core priorities, we have a unique opportunity to help organizations responsibly innovate for the benefit of citizens and residents across the UAE."

12:17 EDT Verizon, NFL announce 40% offer on NFL+ Premium annual subscription on +play - Verizon and the NFL have partnered to give fans "yet another exciting offer to catch the game-winning plays: Starting today, save 40% on an NFL+ Premium annual subscription through +play. That's a full season of NFL+ Premium - which includes access to live local and primetime games on mobile, NFL RedZone, NFL Network, game replays and more - for just $59.99. The offer is only available for a limited time, so the clock's running to get in."

12:00 EDT Manchester United falls -18.5% - Manchester United is down -18.5%, or -$4.38 to $19.28.

12:00 EDT Brady rises 12.0% - Brady is up 12.0%, or $6.08 to $56.88.

12:00 EDT WeWork rises 3100.1% - WeWork is up 3100.1%, or $3.41 to $3.52.

11:51 EDT LVMH's Thelios acquires French eyewear brand Vuarnet - LVMH's Thelios announced the acquisition from NEO Investment Partners of Vuarnet, a French high-end outdoor sunglass brand. "We are thrilled to announce the acquisition of Vuarnet, becoming Thelios' first proprietary brand" said Alessandro Zanardo, CEO of Thelios, "Vuarnet is a legendary brand, with a unique history that deserves to be preserved and perpetuated. Its iconic design, its unique know-how on mineral lenses and its strong brand values, are a perfect match with our ethos and positioning." Terms of the deal were not disclosed. Reference Link

11:38 EDT Microsoft rolls out Xbox dashboard update that includes Discord streaming - Microsoft said it is rolling out a new dashboard update for Xbox consoles that will bring users the ability to stream Xbox gameplay to Discord. "Additionally, we are updating the variable refresh rate for Xbox Series X S consoles, giving you new places to view and redeem Rewards, and providing new wish list notifications to track your games," the company said. "We're continuing our commitment to safety on our platform by rolling out Xbox voice reporting, which allows you to report inappropriate in-game voice chat. On PC, we have some great updates that allow you to easily navigate your library and track the countdown to a game launch." Reference Link

10:41 EDT EVI Industries completes acquisition of ALCO Washer Center - EVI Industries completed the previously announced acquisition of New Castle, Pennsylvania based ALVF, Inc. dba ALCO Washer Center. ALCO is a distributor of commercial laundry products and a provider of related technical installation and maintenance services to the on-premise and vended laundry segments of the commercial laundry industry. The addition of ALCO enhances EVI's distribution, service, and installation capabilities to its growing customer base across the northeast region of the United States.

10:25 EDT Mayfair Gold announces discovery at Fenn-Gib gold project - Mayfair Gold announced the discovery of a new zone of gold mineralization at the Company's 100% controlled Fenn-Gib Project, located in the Timmins region of Northeast Ontario. Fenn-Gib hosts a NI 43-101 open-pit constrained Indicated mineral resource estimate of 3.38 million ounces gold at a grade of 0.93 grams per tonne Au, and an Inferred mineral resource of 0.16Moz Au at 0.85 g/t Au. The Contact Zone was discovered in the first two of five planned deep holes testing mineralization below the pit-constrained resource. Mayfair Gold President and CEO Patrick Evans commented: "Successful exploration is a key driver of shareholder value. Since acquiring Fenn-Gib thirty-two months ago, we have increased the pit-constrained resource by over 70 percent, continued delineation of the adjacent higher-grade Footwall Zone discovery, and now made a new discovery at the Contact Zone. These significant achievements are credited to the knowledge, experience, and dedication of Mayfair's entire exploration team under the leadership of Howard Bird, Vice President Exploration and Paul Degagne, Manager Exploration." Highlight Contact Zone drill results include: FG23-350A intersected 1.06 g/t Au over 124.0m, with higher grade intervals including 3.22 g/t Au over 11.0m; FG23-356 intersected 1.16 g/t Au over 421.0m, including higher grade intervals 12.42 g/t Au over 10.0m and 76.12 g/t over 1.5m. The new zone of mineralization, called the Contact Zone, is located within the mafic volcanics below the Main Zone of the Fenn-Gib deposit. Both holes FG23-350A and FG23-356 intersected substantial widths of gold mineralized altered mafic volcanic rocks situated below the contact of the predominantly syenite intrusive body that comprises the Main Zone of the Fenn-Gib deposit. Discovery of the Contact Zone is significant as it confirms the continuation of gold mineralization at depth below the bottom of the current pit-constrained resource. In addition, the higher-grade gold internal intersections demonstrate the potential for underground mineable grades and widths.

10:17 EDT Helius Medical Technologies Inc trading halted, volatility trading pause

10:03 EDT Newmark secures corporate services contract renewal with Hancock Whitney Bank - Newmark (NMRK) announces that its Global Corporate Services division has been awarded a long-term renewal with Hancock Whitney Bank (HWC), further extending the more than decade-long client service contract and relationship. Hancock Whitney has 180 locations across six states in the Gulf Coast region, accommodating approximately 3,600 employees, Newmark notes. We are proud to extend our relationship with Hancock Whitney and continue leveraging Newmark's broad range of expertise to add value to their real estate portfolio," said Rick Bertasi, Newmark CEO, Global Corporate Services.

10:00 EDT Manchester United falls -15.2% - Manchester United is down -15.2%, or -$3.59 to $20.07.

10:00 EDT Trinseo falls -17.1% - Trinseo is down -17.1%, or -$1.84 to $8.91.

10:00 EDT Brady rises 11.0% - Brady is up 11.0%, or $5.59 to $56.39.

09:56 EDT MasterCard says WSJ report 'wrong,' not raising interchange rates - MasterCard said in a post on its website, "Last Wednesday, several media outlets covered a story from the Wall Street Journal about 'credit card fees.' Unfortunately, the story is wrong. The reporting relies upon a report produced by an advisory firm advocating for legislation currently under consideration in Congress. We want to ensure the correct facts are associated with Mastercard and are understood. They are simple and clear: Mastercard is not raising interchange rates in the U.S. this Fall and has no plans to do so; Mastercard is not raising network fees in the U.S. required for the processing of Mastercard transactions this Fall; The Authorization Optimizerservice is the only Mastercard fee noted in the study cited by the Journal. It is not related to This service is designed to reduce the likelihood that subscription and recurring payments will be declined, with any related fees being de minimis in scope; The article notes that Congress is considering legislation thatcould potentially lower costs for merchants, yet it fails to mention the negative consequences for consumers - compromised security, a loss of rewards programs and higher prices on goods and services. For example, after similar legislation pertaining to debit transactions was passed in 2010, the Federal Reserve of Richmond concluded that consumer prices increased. Whether businesses are considering implementing a specific service or Congress is considering legislation, we believe these activities should only take place based on an accurate understanding of the facts and how our industry works." Reference Link

09:52 EDT Visa says recent press coverage on interchange fees 'misleading'

09:48 EDT Qualcomm to supply Mercedes, BMW with chips for displays - Qualcomm (QCOM) announced it will supply chips to power in-car infotainment systems to luxury automakers Mercedes (MBGYY) and BMW (BMWYY). The latter and Qualcomm Technologies said they have extended a technology collaboration beyond driver assistance and automated driving technologies, bringing the latest Snapdragon Digital Chassis Solution advancements to power BMW Group's new vehicles for "safer, smarter and sophisticated experiences to drivers and passengers." Leveraging both companies' expertise in innovation, BMW is working with Qualcomm Technologies as the automaker's systems solutions provider, to utilize the latest generation of the Snapdragon Cockpit Platform to power BMW Group's new in-vehicle experiences, as well as the Snapdragon Auto Connectivity Platforms for 5G connectivity to bring ultra-fast and seamless connectivity to vehicles with new BMW iDrive generation "QuickSelect" and new Operating Systems 8.5 and 9. As a part of the companies' technology collaboration, BMW and Qualcomm are currently co-developing a comprehensive, open and scalable ADAS system ranging from New Car Assessment Program, Level 2 Advanced Driving Assistance Systems to Level 3 High Automated Driving functionalities to expand the accessibility of safer self-driving technologies to the global automotive ecosystem. These will be based on the Snapdragon Ride Platform with an integrated Ride Vision software stack and the first L2+ systems are expected to be available beginning in 2025. Qualcomm also announced the company's work with Mercedes-Benz AG to continue delivering the digital luxury experience the automaker is widely known for. "As a part of the companies' continued technology collaboration, Snapdragon Digital Chassis Solutions are designed to help bring the latest in-vehicle technology and features to the new 2024 Mercedes-Benz E-Class Sedan. With the next generation Snapdragon Cockpit and Snapdragon(R) Auto Connectivity Platforms, Qualcomm Technologies delivers immersive, interactive and intelligent in-vehicle experiences complete with 5G connectivity and cloud-connected digital services for all occupants. Vehicles featuring the Snapdragon Digital Chassis solutions are expected to be available in the US at the beginning of 2024. Working with Bosch as the system integrator and Tier-1 supplier, the latest generation of Snapdragon Cockpit Platforms help power the new Mercedes-Benz E-Class User Experience multimedia system running on the new MBUX Superscreen, helping to deliver enhanced graphics, rich multimedia support. The Snapdragon Cockpit Platforms also help power the MBUX's high-resolution widescreen unit with touchscreen operation, navigational display and augmented reality technology, providing convenience and more enjoyment for occupants. The Snapdragon Cockpit Platform's pre-integrated support for Wi-Fi 6 and Bluetooth 5.2, feature premium in-vehicle wireless connectivity, including hotspot and high-speed gaming."

09:47 EDT Manchester United falls -10.8% - Manchester United is down -10.8%, or -$2.56 to $21.10.

09:47 EDT Trinseo falls -12.8% - Trinseo is down -12.8%, or -$1.38 to $9.38.

09:47 EDT Brady rises 10.9% - Brady is up 10.9%, or $5.52 to $56.32.

09:37 EDT Knightscope, RippleLink partner to offer Private LTE design, deployment services - Knightscope announces a collaboration with RippleLink to offer Private LTE design and deployment services to provide dramatically improved connectivity with Knightscope's Autonomous Security Robot service over traditional, public use cellular service. As a wireless technology, Private LTE delivers the reliability, performance, security and low latency needed to support the best possible customer experience when using the ASR platform. RippleLink will supply all of the hardware, software, design, RF planning, implementation, RF validation and support to allow Knightscope to include the option of a high-performance wireless network to its ASR clients.

09:35 EDT Nano Dimension appoints COO Tomer Pinchas as acting CFO - Nano Dimension announced that Nano's COO Tomer Pinchas has been appointed as CFO and COO, covering the responsibilities of Nano CFO Yael Sandler while she is on maternity leave. Pinchas has served as Nano's COO for the past year.

09:30 EDT TradeUP Acquisition Corp trading halted, volatility trading pause

09:26 EDT Lithium Corp. optionee James Brown named interim CEO of Sayona Mining - Lithium Corporation (LTUM) wishes to advise investors Mr. James Brown, Managing Director of Morella Corp., Lithium Corporation's largest shareholder and Optionee on the Company's Fish Lake Valley and North Big Smoky Carvers prospects, was recently appointed interim CEO, Sayona Mining (SYAXF). Brown, previously a non-executive Director of Sayona, will guide Sayona through a transitional phase in operations and corporate structure. Lithium Corporation is confident the appointment will not impact Morella Corp.'s activities as Optionee on the Company's Nevada prospects, nor James's duties as a Director of Lithium Corporation. Morella recently concluded a sonic drill campaign on Lithium Corp.'s North Big Smoky Carvers prospect. Final preparations are underway to commence drilling on the Fish Lake Valley prospect.

09:23 EDT Stellantis reports eFuel compability with 24 European engine families - Stellantis has concluded that 24 engine families in European vehicles sold since 2014, representing 28 million vehicles on the road, are ready to use advanced drop-in eFuel without any powertrain modification, following months of testing at its technical centers across Europe. The tests were conducted using surrogate eFuels provided by Aramco, an integrated energy and chemicals company. Low-carbon eFuel is a drop-in synthetic fuel made by reacting CO2 with renewable hydrogen. The use of low-carbon eFuel has the potential to reduce carbon dioxide emissions from existing internal combustion vehicles by at least 70% on a lifecycle basis, compared to conventional fuels. Stellantis aims to halve its carbon footprint by 2030, benchmarking 2021 metrics, and achieve carbon net zero by 2038. Testing of the surrogate eFuels by Stellantis covers tailpipe emissions, startability, engine power, reliability endurance, oil dilution, fuel tank, fuel lines and filters, as well as fuel performance in extreme cold and hot temperatures. Aramco is currently working on two demonstration plants to explore production of low-carbon synthetic fuels in Saudi Arabia and Bilbao, Spain.

09:20 EDT Crown Electrokinetics regains compliance with Nasdaq listing rules - Crown Electrokinetics announced that on September 1, 2023, the Company was notified by The Nasdaq Stock Market that the Company has regained compliance with all applicable requirements for continued listing on The Nasdaq Capital Market. The Company was also notified that, in accordance with Nasdaq Listing Rule 5815(d)(4)(B), the Company will be subject to a "Panel Monitor" through September 1, 2024. If, within that one-year monitoring period, the Company falls out of compliance with the minimum equity requirement for continued listing on the Capital Market, and notwithstanding Nasdaq Listing Rule 5810(c)(2), the Company will not be permitted to provide the Listing Qualifications Department with a compliance plan and the Staff will not be permitted to grant additional time to the Company to regain compliance. Instead, the Staff will issue a delist letter and the Company will have an opportunity to request a new hearing before the Panel, which request will stay any delisting action by the Staff.

09:19 EDT CPS Technologies receives $7.7M award - CPS Technologies received an award, valued at approximately $7.7 million, from a major, longstanding customer to provide power module components and related solutions. Deliveries will take place over a twelve-month period starting in the fourth quarter of this year, with the contract representing a 50% increase over the prior four quarters. The systems will be employed primarily in high-speed rail, wind turbines and EV/HEV applications, and the client company is a multinational semiconductor manufacturer based overseas. Additional details were not disclosed.

09:17 EDT Xos Hub now eligible for $160K CARB CORE incentive - Xos' Xos Hub mobile charging unit is now eligible for the California Clean Air Resources Board's - CARB - Clean Off-Road Equipment Voucher Incentive Project, or CORE. Xos customers are eligible to receive $160K in savings on their purchase of the Xos Hub as a result. The CORE program provides point-of-sale discounts to off-set eligible zero-emission technologies. The CORE project applies to California-based purchases and leases of zero-emission off-road equipment. In addition, the incentive includes no scrappage requirement. Additional funding is available for certain charging and fueling infrastructure, equipment deployed in disadvantaged communities, and purchases of equipment by small businesses.

09:15 EDT Stran & Company resumes stock repurchase program - Stran & Company has resumed its previously announced stock repurchase program and noted recent management stock purchases. The company's Board authorized a stock repurchase program in February 2022 under which the company may repurchase up to $10M of its outstanding shares of common stock in the open market. The company has repurchased approximately $3.3M worth of stock as of June 30. Members of company management have also reported purchases of the company's stock in the open market. There is no defined number of shares to be repurchased over a specified timeframe through the life of the stock repurchase program. The repurchase authorization has no expiration date but may be suspended or discontinued at any time. Stock repurchases are paid using cash generated by operations.

09:15 EDT MHRA approves Pfizer/BioNTech's Omicron XBB.1.5 adapted COVID-19 vaccine - Approval has been granted by the Medicines and Healthcare products Regulatory Agency, or MHRA, for an adapted Pfizer (PFE) and BioNTech (BNTX) COVID-19 vaccine that targets the Omicron XBB 1.5 subvariant, after it was found to meet the UK regulator's standards of safety, quality and effectiveness, the group announced. The vaccine has been approved for use in individuals from 6 months of age. Reference Link

09:14 EDT Manchester United sinks 12% after Daily Mail says team off market

09:12 EDT CleanSpark mined 659 bitcoin in August - CleanSpark released its unaudited bitcoin mining and operations update for the month ending August 31, 2023. "August was another banner month for CleanSpark," said CEO Zach Bradford."August was another banner month for CleanSpark as the 50MW expansion in Washington saw its first full month at maximum operational hashrate, delivering some of our highest daily production ever," said CleanSpark CEO Zach Bradford. "What's more, we have carefully managed power to achieve substantially high levels of uptime in August, despite historically high levels of rain and very hot weather. That operational prowess has resulted in what we expect is among the best monthly bitcoin production rates of publicly traded miners in North America." August Bitcoin Mining Update: Bitcoin mined in August: 659; CY2023 bitcoin mined: 4,729; Total BTC holdings as of August 31: 1,677; Total BTC sold in August: 43; Deployed fleet: 88,217; Month-end fleet efficiency: 28.7; Current hashrate: 9.3 EH/s; The Company sold 43 bitcoins in August 2023 at an average of approximately $28,200 per BTC. Sales of BTC equated to proceeds of approximately $1.2 million. August daily BTC mined averaged 21.26 and reached a high of 22.11.

09:11 EDT Neptune Retail completes its acquisition of Quotient Technology - Neptune Retail Solutions today announced the completion of its acquisition of Quotient Technology Inc. William Redmond, Jr., Neptune Chief Executive Officer, said "We are excited to close on this accretive acquisition and are beginning the integration of Quotient technology, systems, products and infrastructure today."

09:10 EDT MetroCity Bankshares announces new share repurchase program, up to 1M shares - MetroCity Bankshares announced today that on September 1, 2023, its board of directors adopted a new repurchase program authorizing the Company to repurchase up to 1,000,000 shares of the Company's outstanding shares of common stock. The share repurchase program will begin on September 6, 2023 and end on September 30, 2024.

09:09 EDT PDF Solutions launches freemium entry point for Exensio Analytics Platform - PDF Solutions announced the launch of a freemium entry point for its Exensio Analytics Platform, providing users a new way to start using and experience the market-leading analytics platform. At this entry point, users can access and use limited, off-line features of the Exensio Analytics Platform for insights into their yield and test operations through a thin client architecture. This will give them access to a subset of offline data anytime, anywhere. It provides highly-interactive tools designed to quickly identify and characterize yield and test problems, drill down into their root causes, and templates to create rules for outlier detection and escape prevention. Built on a big data structure, the Exensio Analytics Platform is designed to power fast, high-volume, scalable storage and analysis, and automate data wrangling, integration, and alignment. New users - or existing customers - can utilize the freemium option to try new applications before they buy. The freemium-level Exensio Analytics Platform includes the following functionality: Exensio Manufacturing Analytics is designed to provide efficient yield monitoring and powerful tools for root cause analysis and automation and reporting for new product introduction and production yield management. Exensio Test Operations Lite is designed to monitor and optimize test programs, equipment, and outlier detection for test operations analytics and optimization. Exensio Automation and Reporting is designed to provide out-of-the-box reporting templates for management level reporting.

09:09 EDT Kennametal joins NASCAR competition partner program - Kennametal announced that it is a new NASCAR Competition Partner, a program developed by the global auto racing company to highlight the innovations of the highest-quality auto performance suppliers. As a contributing company in the program, Kennametal will supply its portfolio of precision metal cutting solutions for use in the further development of NASCAR's Next Gen cars. "Kennametal is led by innovation and driven by forward thinking, so teaming up with the world's most recognized racing brand to deliver next generation solutions just makes sense," said Sanjay Chowbey, President of the Metal Cutting Segment at Kennametal. "Our legacy in the automotive industry is well-established, and as a NASCAR Competition Partner, we can connect with new audiences and further showcase our capabilities."

09:08 EDT LPL Financial announces Ed Winegar, Gregory Berg join Linsco - LPL Financial announced that financial advisors Ed Winegar and Gregory Berg have joined LPL's employee advisor channel, Linsco by LPL Financial, to launch Winegar Berg Wealth Management Powered by LPL Financial. They reported having served approximately $205 million in advisory, brokerage and retirement plan assets and join LPL from Merrill Lynch.

09:07 EDT Advent secures $1.3M contract to supply eFuel-powered fuel cell stacks - Advent Technologies Holdings is pleased to announce a significant expansion order contract with a prominent fuel cell integrator operating in the Asian market. Under the terms of this agreement, Advent will provide its innovative eFuel-powered fuel cell stacks to be incorporated in power applications within the leisure sector in the region. The contract has a total initial value of $ 1.3M . Deliveries are expected to commence in September 2023, with the supply chain projected to remain active throughout 2024 in accord with the customer's specified timeline. The primary application of Advent's fuel cell stacks is to serve as sustainable prime and back-up power sources in small cabins, working in conjunction with batteries. The market for portable fuel cells, especially in the context of the leisure industry, is currently niche. However, because of the requirement to reduce carbon and other particulate emissions, this upswing in demand can be attributed to the increasing need for compact and portable fuel cell systems that are tailored to various leisure-related applications. The utilization of Advent's Serene fuel cell stacks using liquid methanol as a hydrogen carrier fuel offers advantages in terms of transportation, logistics, and storage efficiency compared to gaseous hydrogen, thus enhancing operational safety.

09:07 EDT Bit Origin provides production and operation update for August 2023 - Bit Origin provided its production and operation update for August 2023. As of August 31, the total mining hash rate stands at 403 PH/s with 4,250 miners installed in the Indiana facility, representing all miners the company has purchased. The company mined 23.5 Bitcoins and achieved a revenue of $655,647 in August 2023. As of August 31, the company has one hosting mining site in operation and one mining site under development. The company ceased its operation in the mining facility in Georgia from December 31, 2022. Phase I of the Project of a capacity of up to 45MW for the mining facility in Wyoming was energized in March 2023. The Phase II of 25MW is undergoing engineering design process currently.

09:05 EDT Nokia selected as rural broadband PON solution for Mediacom - Nokia announced that Mediacom is building PON networks to provide multi-gigabit broadband service to rural, underserved communities. Fueled partly by state and federal grant projects, Mediacom will leverage Nokia's XGS-PON systems and equipment, to support new geographical serving areas.

08:53 EDT Brady jumps 9% to $55.51 after Q4 earnings beat, above-consensus guidance

08:47 EDT Tomi Environmental Solutions' BIT recognized by USDA as potential bee solution - Tomi Environmental Solutions announced the completion of a study funded by the U.S. Department of Agriculture - USDA - and the National Institute of Food and Agriculture - NIFA - which demonstrated SteraMist iHP as an effective treatment of deformed wing virus contaminated hive substrates. The study aimed to determine if the use of cold plasma ionized hydrogen peroxide can reduce the infectivity of DWV to naive honey bee pupae. Widespread colony collapse could result in a significant decline in the diversity of fresh produce and substantially impact human nutrition on a global scale. It is of critical importance for the USDA and NIFA to identify a non-toxic, quick, and effective disinfection system capable of deactivating latent DWV on hive substrates. The study utilized a SteraMist Environment System along with Tomi's Binary Ionization Technology solution. The findings confirmed the efficacy of iHP as an effective method for pathogen decontamination of deformed wing virus in honey bee substrate. Additionally, iHP treatment was found to achieve higher levels of DWV inactivation at a substantially shorter treatment duration when compared to ethylene oxide treatment or gamma irradiation.

08:46 EDT Yoshiharu authorizes $1M share repurchase program - Yoshiharu Global announced that its board of directors has approved a share repurchase authorization of up to $1,000,000 worth of the Company's common stock.

08:44 EDT Quisitive Technology achieves 15th, 16th Microsoft advanced specializations - Quisitive Technology Solutions has achieved the Information Protection and Governance and Service advanced specializations, marking the 15th and 16th Microsoft advanced specializations awarded to the Company.

08:43 EDT Ascent Solar increases cell production efficiency - Ascent Solar Technologies has achieved cell production efficiency of 15.2% in its CIGS solar technology, a significant increase from the 10.8% standard efficiency measured for production material in 2012. This increase is attributed to the targeted optimization of the existing Cadmium Sulfide deposition and manufacturing processes behind the Company's CIGS technology. Parallel development efforts have been successful in the replacement of the Cds deposition in the production process. Cds is a known harsh material, which ASTI has strategically sought to shift away from, to limit hazardous production components and eliminate the need for specialty waste mitigation processes. The preliminary efficiency measurements of this next generation material indicate that yields are 5% to 8% higher than that of Cds, which would translate to a theoretical efficiency of 16% to 16.4%. With continued promising results such as these production trials, the Ascent team is redefining what is possible for thin-film CIGS technology efficiencies through consistent ongoing process optimization, guided by decades of manufacturing experience.

08:42 EDT Metals Acquisition appoints Patrice Merrin as Chair of the Board of Directors - Metals Acquisition announced the appointment of Ms. Patrice Merrin as Chair of the Board of Directors. Ms. Merrin replaces Mr. Neville Power who has resigned from the Board to pursue other opportunities. .

08:42 EDT Travere Therapeutics completes sale of bile acid product portfolio - Travere Therapeutics (TVTX) and Mirum Pharmaceuticals (MIRM) announced the completion of the previously announced sale of Travere's bile acid product portfolio that includes Cholbam and Chenodal, two medications addressing rare diseases in high-need settings. In connection with the closing of the Asset Purchase, Travere received an upfront payment of $210 million from Mirum, and remains eligible to receive up to $235 million in potential sales-based milestone payments. Mirum has acquired Travere's rights to Cholbam, indicated for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms of liver disease, and Chenodal, indicated for the treatment of radiolucent stones in the gallbladder, which is also under Phase 3 clinical evaluation for cerebrotendinous xanthomatosis. The closing of the Asset Purchase was subject to the satisfaction of customary closing conditions, including the expiration of the waiting period under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976. In connection with the closing, Travere will provide certain transitional services to Mirum.

08:40 EDT EMA validates Arcturus/CS's MA application for ARCT-154 vaccine to prevent Covid - Arcturus Therapeutics Holdings and CSL, and its vaccine business, CSL Seqirus announced that the European Medicines Agency, EMA, has validated the marketing authorization application or MA,A for ARCT-154, a next generation mRNA vaccine, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older. The companies anticipate an approval decision by the European Commission in 2024. The EMA submission is based on successful Phase 3 clinical results of ARCT-154 against the ancestral D614G variant as a primary series and booster. In an analysis of 6-month data from the pivotal Phase 3 study, the primary efficacy endpoint was met and ARCT-154 as a primary series resulted in 56.6% efficacy for prevention of symptomatic COVID-19 overall, and 95.3% efficacy for prevention of severe COVID-19 including COVID-19 related deaths. The study was conducted when Delta variant was dominant in Vietnam. The booster data result was previously announced by CSL Seqirus' partner, Meiji Seika Pharma, indicating that the primary endpoint was achieved in a Phase 3 booster vaccine study by demonstrating non-inferiority of immune response against SARS-CoV-2 ancestral strain compared to Comirnaty(R). Superiority of ARCT-154 in neutralizing antibody response against SARS-CoV-2 Omicron BA.4/5 variant was a key secondary endpoint. "EMA acceptance of the marketing application for ARCT-154 represents another major achievement in the development of this innovative mRNA vaccine platform. This is also an important milestone for Arcturus and our global exclusive partner, CSL Seqirus, as we work towards achieving approval in Europe," said Joseph Payne, President & CEO of Arcturus Therapeutics. "ARCT-154 is expected to be efficiently updated as new variants of concern arise and has the potential to be a longer lasting vaccine against the pervasive and ever-changing COVID virus."

08:40 EDT Apple to acquire classical music label BIS Records - BIS Records, a Swedish classical music record label, announced via Twitter: "After 50 years, BIS Records is proud to announce that we have joined the Apple family. BIS will become part of Apple Music Classical and Platoon. In this way, the musical treasures of our extensive catalogue will be further enhanced and preserved." Terms of the deal have not been disclosed. Reference Link

08:39 EDT BTC Digital provides updates on digital currency business for Q2 - BTC Digital provided updates on the Company's digital currency business for the second quarter of 2023. As of June 30, 2023, BTC Digital had deployed a total of 1,754 BTC miners in operation, with a total mining hash rate of 188PH/s and a total output of 35.07 BTC. At the beginning of August 2023, 200 S19J PRO mining machines acquired by the Company through share issuance have been deployed, and the mining hash rate has been increased by 22 PH/s. The Company plans to acquire additional units of BTC miners by the end of 2023 through issuing shares, effecting mergers and acquisitions, or with proceeds of financings. The Company is currently negotiating with potential sellers for the acquisition of mining machines. Alan Peng, CEO of BTC Digital, said: "As an emerging growth company engaged in cryptocurrency mining, we are pleased to see the Company's BTC mining business actively expanding, and the Company intends to take necessary measures to utilize resources to increase aggregate computing power. Our long-term goal is to have 15,000 units of our own mining machines in operation, and the Company expects to actively seize additional business opportunities in cooperating with business partners to increase the probability of achieving the long-term goal."

08:37 EDT America's Car-Mart apoints Doug Campbell as CEO - America's Car-Mart has elected current President Doug Campbell to succeed Jeff Williams as CEO and to serve as a director of the company, each effective October 1. Williams will remain with the company as CEO Emeritus through the end of FY24. Williams will also continue his service on the board. Before joining America's Car-Mart in October 2022, Campbell was Senior VP, Head of Fleet Services for the Americas, at Avis Budget Group after serving as Vice President of Remarketing leading their wholesale, retail, and factory program disposals. Prior to joining Avis Budget Group, he worked for AutoNation in both corporate and field leadership roles. Previously, he spent 15 years at Coral Springs Auto Mall as an Executive General Manager overseeing several brands selling both new and used vehicles. Campbell will continue to serve as President of the Company upon his appointment as CEO.

08:35 EDT TC Biopharm announces grant funding in collaboration with QMUL - TC BioPharm announces it has entered into a collaboration agreement with Queen Mary University of London, QMUL, to research the therapeutic potential of gamma-delta T cells for the treatment of mucosal infections. The collaboration recently received grant funding from The Impact Fund arm of QMUL. TC BioPharm will be working in conjunction with Dr. Neil McCarthy's lab out of QMUL. "We are grateful for the support from the Queen Mary University of London Impact Fund and appreciate Dr. McCarthy and his team taking this initiative on with enthusiasm," said Bryan Kobel, CEO of TC BioPharm. "Dr. McCarthy's lab is a leading institution in the gamma delta field focusing on gut health and microbial infections, a great area of interest for TCB. This is an exciting opportunity for our company and QMUL, the collaboration is a good starting point for both groups with the potential to extend into future engagements and asset spinoffs, while simultaneously expanding the TCB-008 platform into new indications. We believe the data set here and in future endeavors will further showcase the therapeutic benefit of the gamma delta T-cells centering around their role in immunotherapy's future.

08:34 EDT Pioneer Power received purchase orders for $7M in August - Pioneer Power Solutions announced that it has received purchase orders for $7M during the month of August for its E-Bloc distributed generation solution and other related custom control and protection equipment. The orders, which are from several customers and address a diverse set of verticals and use-cases, are scheduled for delivery starting in the second quarter of 2024 with the majority to be recognized in the second half of 2024. Use-cases include EV supercharging stations, electrical utility customers, and aerospace customers. "The distributed generation trend is here, with more and more customers taking steps to provide energy resilience, especially in light of severe weather events, and to efficiently utilize renewable energy sources like solar and wind," noted Nathan Mazurek, Pioneer Power's Chairman and Chief Executive Officer. "Our E-Bloc solution addresses these business needs, ensuring a secure supply of electricity without exclusively relying on the grid. E-Bloc also enables our customers to achieve an improved carbon footprint through the use of renewable sources and energy storage to augment the utility grid. Finally, and importantly, E-Bloc helps customers more efficiently manage their energy costs through peak shaving and other strategies."

08:33 EDT ParaZero to showcase safety systems for commercial drones - ParaZero Technologies announces its participation in the upcoming Commercial UAV Expo in Las Vegas, Nevada, on September 5-7, 2023. The Company to showcase its autonomous safety systems for commercial drone and urban air mobility aircraft. The Commercial UAV Expo is an important international trade show and conference highlighting leading unmanned aircraft systems trends and technology, focusing on the evolving global interest and demand for integrated drone technology solutions for a wide range of commercial and other applications.

08:23 EDT TFI International acquires Vedder Transportation Group in Canada - TFI International acquired Vedder Transportation Group, which specializes in the tank truck transport of food grade liquids and dry bulk commodities. Headquartered in Abbotsford, British Columbia where it began operations in 1956, Vedder was one of the first companies in Western Canada to use tanker trucks to transport liquid food grade products, with operations now spanning British Columbia to Manitoba. Vedder generates annual revenues in excess of C$80M. Run by President Fred Zweep, Vedder will join TFI International's Specialized Truckload business segment.

08:22 EDT HomeTrust appoints Lora Jex as EVP, CRO - The board of directors of HomeTrust Bancshares, announced that Lora Jex assumed the position of Executive Vice President and Chief Risk Officer of both the Company and the Bank effective August 31, 2023. Ms. Jex will lead the HTB teams responsible for monitoring and mitigating risk for the Bank related to compliance, operations, balance sheet management, and strategy. As such she will have oversight of assessing and maturing HTB's risk appetite to further advance the Bank's enterprise risk management approach. Ms. Jex will serve as a member of the Operating Committee and report functionally to the Bank's Audit Committee and administratively to C. Hunter Westbrook, President & Chief Executive Officer of HTB. Prior to joining HTB, she served as Chief Compliance Officer at Southern First Bank in Greenville, SC and at South State Bank in Columbia, SC.

08:21 EDT ScanTech Identification to become publicly listed via combination with Mars - ScanTech Identification Beam Systems and Mars Acquisition (MARX) announced that they have entered into a definitive business combination agreement that will result in ScanTech becoming a publicly listed company. Pursuant to the Business Combination Agreement, each of ScanTech and Mars will merge with newly-formed subsidiaries of ScanTech AI Systems Inc., a newly-formed Delaware holding company, and Pubco will be the parent company of each of ScanTech and Mars following the consummation of the transaction. Upon the closing of the transaction, Pubco is expected to be listed on Nasdaq under the ticker symbol "STAI". Transaction Overview: The combined company is expected to have an estimated post-transaction enterprise value of $149.5 million, consisting of an estimated equity value of $197.5 million and $48 million in net cash, assuming no redemptions by Mars' public shareholders. Net cash will come from Mars' approximately $72 million of cash in trust. Upon the closing of the transaction, and assuming none of Mars' public shareholders elect to redeem their ordinary shares and that no additional shares are issued upon the closing of the transaction, it is anticipated that (i) Mars' public shareholders will retain an ownership interest of approximately 42% of the combined company, (ii) the sponsors, officers, directors and other holders of Mars founder shares will retain an ownership interest of approximately 12% of the combined company, and (iii) the ScanTech security holders will own approximately 46% of the combined company. The Business Combination has been unanimously approved by the boards of directors of both ScanTech and Mars and is expected to close in the first quarter of 2024, subject to regulatory and shareholder or member approvals, and other customary closing conditions.

08:19 EDT Casella Waste completes acquisition of Consolidated Waste Services assets - Casella Waste completed the acquisition of the collection, transfer, and recycling assets of Consolidated Waste Services and its affiliates on September 1. The purchase price of the acquisition was approximately $219M and was funded through proceeds from the company's equity offering completed on June 16. The acquisition includes two hauling operations, one transfer station, and one material recovery facility in the greater Albany, New York market, and is expected to generate total annualized revenues of approximately $70M.

08:18 EDT Canacol Energy says gas sales averaged 178 MMscfpd in August - Canacol Energy provides the following gas sales and drilling operations update. Realized contractual natural gas sales (which are gas produced, delivered, and paid for) were 178 million standard cubic feet per day for August 2023. Commencing the second week of August 2023 the Corporation experienced unusual and unexpected production capacity restrictions at some of its gas fields as a result of issues at the Jobo gas treatment facility as well as certain of its producing wells. As a result of the foregoing the Corporation has had to restrict gas deliveries under certain supply contracts dedicated to supplying non-essential gas demand, all in accordance with applicable Colombian regulations and in consultation with the relevant authorities. The Corporation is presently working on remediating this short-term disruption and expects to have production back to normal levels shortly. The Corporation spud the Cereza 1 exploration well on August 9, 2023 and reached a TD of 7,650 feet measured depth on August 20, 2023. The well encountered noncommercial quantities of gas within the Cienaga de Oro sandstone reservoir and was plugged and abandoned. The Corporation is currently drilling the Fresa 2 appraisal well targeting sandstones of the CDO reservoir that are productive in the offsetting Fresa 1 exploration well drilled in 2021. The Corporation anticipates completing the drilling of the well within the next two weeks. Two drilling rigs are currently being mobilized to drill the Agua Vivas 4 and Pandereta 9 development wells, with expected spud dates of the second week of September 2023 and the first week of October 2023 respectively. Both are infill development wells, and each will take approximately 4 weeks to drill and complete. The Corporation is focusing on infill development drilling and workover opportunities to meet anticipated high gas demand during the El Nino season which is anticipated to start in fourth quarter 2023. The company will return to exploration drilling prior to year end.

08:17 EDT Enveric announces new patent related to EB-373 psilocin prodrug for anxiety - Enveric Biosciences announced that the United States Patent and Trademark Office, USPTO, has issued U.S. Patent No. 11,746,087, titled "C-4 Carboxylic Acid Substituted Tryptamine Derivatives and Methods of Using," pertaining to the Company's EVM201 Series and lead candidate EB-373, a psilocin prodrug being developed for the treatment of anxiety disorder. Issued September 5 the new patent provides Enveric with intellectual property rights for compositions and methods for tryptamine-derived prodrugs utilizing C4 carboxylic acid substituted tryptamine derivatives. This patent complements the recently issued U.S. patent titled "C4-Carbonothioate-substituted Tryptamine Derivatives and Methods of Using," providing Enveric with a robust intellectual property portfolio governing psilocin prodrugs designed to potentially elicit a more rapid onset of action, more controlled therapeutic effect, and reduced gastrointestinal side-effects compared to conventional psilocin prodrugs, such as psilocybin. EB-373 was developed from Enveric's EVM201 Series of molecules, which are rationally designed to achieve altered metabolic and pharmacokinetic properties. "Today's patent issuance from the USPTO adds another important pillar to Enveric's intellectual property portfolio as we continue to distinguish our tryptamine-based prodrugs from similar compounds being developed for the treatment of mental health disorders," said Joseph Tucker, Ph.D., Director and CEO of Enveric. "Both our EVM201 Series, led by EB-373, and our EVM301 Series are designed to capitalize on the potential of neuroplastogens that can enhance neuroplasticity while minimizing unwanted side effects, including prolonged and unpredictable hallucinatory experiences. We expect continued positive IP-related developments in the coming months that, we believe, will serve to further highlight the differentiation and value of EB-373 and our EVM201 and EVM301 Series of compounds."

08:16 EDT IceCure Medical's ProSense system receives regulatory approval in Brazil - IceCure Medicalannounced that its ProSense System has received regulatory approval as a Class III device from the Brazilian Health Regulatory Agency. ProSense's disposable cryoprobes and introducers, were previously registered as Class II devices by ANVISA. Applications for both the ProSense System and its disposable cryoprobes and introducers were submitted to ANVISA by IceCure's distributor in Brazil, Ktrfios Importacao e Exportacao LTDA. ProSense's indications approved by ANVISA are oncology, which includes the ablation of benign and malignant tissues in the breast, prostate, kidney, lung, liver, musculoskeletal, and skin tissue, as well as for palliative intervention and other indications. "We are very pleased that ProSense has received regulatory approval in Brazil. We expect this to translate into near-term revenues. Early indications of market interest point to strong demand in the largest market in South America where cost-effective, minimally invasive, safe, and effective cryoablation procedures can offer great benefits compared to traditional surgical interventions," stated IceCure Chief Executive Officer, Eyal Shamir.

08:15 EDT Dare Bioscience completes previously announced equity financing - Dare Bioscience announced the completion of its registered direct offering of common stock and warrants to purchase common stock priced at-the-market under Nasdaq rules with an institutional investor and an investor affiliated with the licensor of one of the company's early stage product candidates. The aggregate gross proceeds to Dare, before deducting offering expenses payable by Dare, were $7.0 million. The closing occurred on September 1, 2023. Dare's completed equity financing included minority participation by an investor affiliated with Douglas.

08:14 EDT LiveOne's PodcastOne signs long-term extension with Kit Gray - LiveOne announced that its subsidiary, PodcastOne, has secured a long contract extension with its Co-Founder and President, Kit Gray.

08:13 EDT Karat Packaging appoints Jian Guo to board of directors - Karat Packaging announced the appointment of its CFO Jian Guo, to the board of directors, effective immediately, filling a vacant seat. Ms. Guo will continue in her role as CFO.

08:13 EDT ABM selected by Providence Public School District for maintenance contract - ABM announced its new partnership with the Providence Public School District in Rhode Island, to enhance the custodial, grounds and maintenance operations of its schools with nearly 22,000 students and teachers. The performance-based term of the contract is for the next three years followed by two 2-year options. All 200 custodial, grounds and maintenance team members previously employed to provide services to PPSD schools under the past contractor were offered roles to join ABM. This new partnership will support the maintenance and upkeep of school facilities as Providence invests more than $600M into its schools.

08:12 EDT Phillips Edison raises monthly dividend by 4.5% to 9.75c per share - Phillips Edison & Company announced that its Board of Directors approved a 4.5% increase to the monthly dividend distributions payable October 2, 2023 and November 1, 2023 to common stockholders of record as of September 15, 2023 and October 16, 2023, respectively. The Board approved the distribution at a rate of $0.0975 per share of the Company's common stock. When annualized, this is equal to a rate of $1.17 per share, representing an increase of 4.5% over the previous annualized rate of $1.12 per share. Operating partnership unit holders receive distributions at the same rate as common stockholders, subject to the required tax withholding.

08:10 EDT Apollo Global, Phoenix launch global origination partnership - Phoenix Holdings and Apollo announced, as part of their ongoing collaboration, they are launching a partnership for the deployment and co-investment of Phoenix client and corporate assets. This partnership will be based on an evergreen structure allowing Phoenix to participate in up to $2 billion of investments as a strategic partner for Apollo in Israel. The partnership aligns Phoenix with one of the most established alternative asset managers in international markets, and provides access to high-quality, privately originated global credit opportunities.

08:09 EDT Cingulate presents full trial results from Phase 3 trial of CTx-1301 - Cingulate announced the presentation of full results from the Phase 3 adult efficacy and safety trial of its lead candidate, CTx-1301, for the treatment of attention deficit/hyperactivity disorder at the 36th Annual Psych Congress, taking place September 6-10, 2023 in Nashville, TN. The poster was accepted as a finalist for the first annual Psych Congress Poster Awards, which will be awarded onsite at the conference. Poster Awards will be on display on Saturday, September 9, from 6:45-8:15pm CT. Ann Childress, M.D., President, Center for Psychiatry and Behavior Medicine, Inc., and lead investigator, will present the full results from the Phase 3 CTx-1301-022 trial. CTx-1301 is a novel, investigational treatment being developed as a true, once-daily stimulant medication for ADHD, upon approval from the U.S. Food and Drug Administration. Last month Cingulate released top-line data from the Phase 3 CTx-1301-022 study, which assessed efficacy and safety along with onset and duration of CTx-1301 in 21 adults with ADHD in an adult laboratory classroom setting. The data demonstrated a trend towards significance in improving ADHD symptoms with a rapid onset of action and entire active-day duration. In addition to the Phase 3 adult dose-optimization study, Cingulate initiated its pivotal Phase 3 fixed-dose pediatric and adolescent study in July 2023, as well as a dose-optimization onset and duration study in pediatric patients in August 2023. Assuming positive clinical results from the Phase 3 trials, Cingulate plans to submit a New Drug Application (NDA) for CTx-1301 in the second half of 2024 under the Section 505(b)(2) pathway.

08:08 EDT Portage Biotech collaborating with Merck to evaluate antitumor combination - Portage Biotech (PRTG) has entered into a clinical trial collaboration agreement with Merck (MRK) to evaluate Portage's next-generation adenosine antagonists in combination with Keytruda - pembrolizumab -, Merck's anti-PD-1 therapy, for patients with solid tumors. The collaboration will explore Portage's adenosine 2A receptor antagonist, PORT-6, its adenosine 2B receptor antagonist, PORT-7, individually and together in combination with Keytruda in prostate, renal, head and neck, colorectal, endometrial, ovarian and non-small cell lung cancers. Under the terms of the agreement, Merck will provide Keytruda for Portage Biotech's ADPORT-601, an adaptive Phase 1a/1b trial which plans to integrate proprietary biomarkers for selecting patients with high adenosine expression in order to identify those more likely to respond and have potential to benefit most from treatment.

08:07 EDT Guardant Health receives regulatory approval in Japan Guardant360 CDx - Guardant Health announced the Japanese Ministry of Health, Labour and Welfare, or MHLW, has approved the Guardant360 CDx liquid biopsy test as a companion diagnostic to select patients with unresectable advanced or recurrent non-small cell lung cancer, or NSCLC, with HER2 mutations that has progressed after chemotherapy for treatment with Enhertu. Enhertu is a specifically engineered HER2-directed antibody drug conjugate developed by Daiichi Sankyo.

08:05 EDT PriceSmart announces opening of tenth warehouse club in Colombia - PriceSmart announced that on September 1, 2023 the Company opened its newest warehouse club in Medellin, Colombia, bringing the total number of warehouse clubs in operation by the Company to 52. The El Poblado club is the second club in Medellin and tenth overall club in Colombia and was constructed on a three-acre property in the El Poblado area.

08:05 EDT Global Crossing Airlines operates over 2,500 block hours in July - Global Crossing Airlines Group provides an update on block hours operated in July and August, aircraft deliveries and contracts signed. "GlobalX operated over 2,500 block hours in July and approximately 2,400 block hours in August, bringing the quarter total to 4,900 compared to 3,157 hours in July and August 2022, a 55% increase. We are continuing the strong momentum gained in July with 9 passenger aircraft and 2 A321 Freighters operating. We expect a strong finish to the 3rd quarter as we transition from our summer flying into our fall program" said Ed Wegel, Chairman and CEO. During Q3 GlobalX has: Taken delivery of our 10th passenger aircraft, N285GX, and it has started revenue operations on September 1; Signed a new $4M ACMI Government contract for September and October - with potential to be extended into a multi-year contract; Closed on a $35 million financing which allows us to add six additional aircraft this year and all planned deliveries in 2024; Signed contracts with two major tour operators each launching new 3 times a week service to Caribbean destinations; Signed contracts with a cargo operator establishing new cargo routes to several Caribbean countries, including Jamaica and Trinidad. Successfully flown for Wizz Air, Lynx Air, TUI and Caribbean Airlines and provided additional lift to our sister company, Canada Jetlines; Signed an LOI for 1 additional A321 passenger aircraft to be delivered in Q4 2023 and 2 additional A321 freighters to be delivered in 2024; Scheduled the delivery of our 11th passenger aircraft, an A320, in October and the 12th passenger aircraft in December 2023; Increased our pilot head count to 123 with another 10 direct entry Captains starting on September 11.

08:04 EDT Nexstar, Fox Corp. renew multi-year affiliation agreement - Nexstar (NXST) and Fox Corp. (FOX) announced that they have reached a comprehensive multi-year agreement renewing the Fox affiliations of 29 Nexstar-owned stations across the United States, including those in six of the country's top twenty markets. In addition, Fox Corporation has reached agreements to renew the FOX affiliations of 12 stations that have shared services agreements with Nexstar, 11 of which are owned by Mission Broadcasting and one of which is owned by White Knight Broadcasting, Inc. Collectively, these 41 television stations renewing their Fox affiliations reach almost 22M television households. Financial terms of these agreements were not disclosed.

08:03 EDT Axcelis announces CFO Brewer to retire, Coogan to succeed - The Board of Directors of Axcelis Technologies (ACLS) named James Coogan to succeed Kevin Brewer as Executive Vice President and Chief Financial Officer. Coogan will join the Company in October 2023. At that time, Brewer will assume the title of Executive Vice President, Finance and Operations. He will continue to manage the Company's manufacturing operations and will support the transition of the Company's finance function to Coogan. Brewer plans to retire at year-end 2023 and will remain as a Senior Advisor through 2024. Coogan joins Axcelis after serving as Senior Vice President, Chief Financial Officer at Kaman (KAMN), a leading provider of aerospace and defense products.

08:00 EDT Recursion completes Phase 1 study for REC-3964 - Recursion has completed the Phase 1 study for REC-3964 in healthy volunteers. The study achieved its primary objectives of assessing the safety, tolerability and pharmacokinetic profile of REC-3964. REC-3964 has been well tolerated with no serious adverse events reported. REC-3964 is a novel non-antibiotic small molecule inhibitor of C. difficile toxins that is being developed for the potential treatment of Clostridioides difficile infection, a bacterial disease that impacts more than 730,000 people in the US and EU5 every year. REC-3964 is Recursion's first and most advanced new chemical entity, demonstrating the power of Recursion's platform to rapidly identify, validate, optimize and translate novel insights into clinical candidates. REC-3964 represents a novel small molecule approach designed to selectively inhibit the toxin produced by Clostridioides difficile in the gastrointestinal tract. This molecule has the potential, when used as part of a treatment regimen, to prevent recurrent disease and/or other forms of C. diff infection, which is a leading cause of antibiotic-induced diarrhea sometimes leading to significant morbidity and mortality. More than 29,000 patients die in the US every year from C. diff infection.

07:52 EDT Global Net Lease, Necessity Retail REIT shareholder supports combination - Blackwells Capital, an alternative investment management firm that is a shareholder of both Global Net Lease (GNL) and The Necessity Retail REIT (RTL) reiterated its support for the companies' proposed combination. Jason Aintabi, chief investment officer of Blackwells, commented: "Blackwells spent the last year engaging with GNL and RTL to secure various enhancements, including corporate governance improvements, that stand to benefit both companies' shareholders for years to come. The Special Committees of GNL and RTL, per the disclosure in the proxies, negotiated multiple internalizations with the external manager in order to create this valuable corporate transformation. We estimate this will save the combined entity more than $75 million annually and give shareholders best-in-class corporate governance, tremendous scale, synergies, AFFO accretion, debt reduction and diversification. The internally managed combination is trading at an implied value of less than half that of its peer set currently, while we believe the merged entity will command a premium valuation as the market comes to understand the strength of a $10 billion REIT platform with all the attributes above."

07:51 EDT Medipharm Labs completes sale of vacant land for cash proceeds of $1.9M - MediPharm Labs announces it has completed the sale of vacant land for net proceeds of $1.9M dollars. On August 30, 2023, MediPharm completed the sale of 291 Kimmett's Side Road, Napanee, Ontario, for net proceeds of $1.9 million. The land has not been utilized since 2021.

07:49 EDT Perella Weinberg Partners appoints Johann von Wersebe as partner - Perella Weinberg Partners announced that Johann von Wersebe has joined the Firm as a Partner in the Advisory Business. Based in Munich, Mr. von Wersebe will lead the Firm's business in the DACH region, further strengthening Perella Weinberg's presence in Europe. Mr. von Wersebe brings over 25 years of investment banking experience to the Firm. He spent the last 17 years at Morgan Stanley where he was Managing Director and Co-Head of Investment Banking for Germany and Austria

07:48 EDT Intel, Tower Semiconductor announce new U.S. foundry agreement - Intel (INTC) and Tower Semiconductor (TSEM) announced an agreement where Intel will provide foundry services and 300mm manufacturing capacity to help Tower serve its customers globally. Under the agreement, Tower will utilize Intel's advanced manufacturing facility in New Mexico. Tower will invest up to $300M to acquire and own equipment and other fixed assets to be installed in the New Mexico facility, providing a new capacity corridor of over 600,000 photo layers per month for Tower's future growth, enabling capacity to support forecasted customer demand for 300mm advanced analog processing.

07:43 EDT Fury Gold Mines appoints Isabelle Cadieux as board director - Fury Gold Mines announced that its Board of Directors has appointed Isabelle Cadieux as an Independent Director, effective immediately. Cadieux, a professional geologist, brings more than 30 years of experience in mineral exploration and financing in the mining sector. She last held the position of Managing Director, Investment at SIDEX, a Quebec institutional fund that finances exploration companies, including Fury, and continues to hold shares in Fury, where she served from 2001 until 2023.

07:42 EDT Bird Construction to lead two post-secondary projects with combined $280M value - Bird Construction has been selected as construction manager for the Vancouver Community College Centre for Clean Energy and Automotive Innovation and the University of Victoria Engineering Expansion Project. The combined value of the contracts is approximately $280 million.

07:38 EDT Dime Community appoints Daniel Shaya Csillag as head of healthcare vertical - Dime Community announced that Daniel Shaya Csillag will join the Company as Group Head of a newly created Healthcare vertical. In this role, Csillag will be responsible for building out Dime's healthcare commercial banking business in the long-term care space. Most recently, Csillag was at Valley National Bank and predecessor institution Bank Leumi, where he was Group Head of Healthcare

07:37 EDT Dime Community appoints Shaya Csillag as head of healthcare vertical - Dime Community announced that Daniel Shaya Csillag will join the Company as Group Head of a newly created Healthcare vertical. In this role, Csillag will be responsible for building out Dime's healthcare commercial banking business in the long-term care space. Most recently, Csillag was at Valley National Bank and predecessor institution Bank Leumi, where he was Group Head of Healthcare

07:35 EDT Mattr announces inclusion in S&P/TSX Composite Index - Shawcor Ltd., dba Mattr Infratech announced its common shares will be added to the S&P/TSX Composite Index, effective prior to market open on Monday, September 18, 2023. The S&P/TSX Composite Index is the headline index and principal benchmark for Canadian equity markets.

07:34 EDT Janover provides Q2 business update - Blake Janover, CEO of Janover, stated, "On July 25, 2023, we achieved historic milestones for our Company by completing an IPO onto the Nasdaq Stock Market and concurrently raising over $5 million. This was a direct result of intensive analysis, planning and hard work by our leadership team and Board of Directors. Despite industry-wide challenges and management's focus on our IPO, we performed well during the second quarter of 2023, with second quarter 2023 revenue increasing to $602 thousand, a 29 percent sequential increase compared to the first quarter of 2023. Although we experienced a modest decline over the second quarter of 2022, we believe we outperformed the broader market by a significant margin, which we believe reflects the efficacy of our business model and the inherent ability of our platform to capitalize on the volatility in the market. It is also important to note that the second quarter of 2022 included a single transaction that significantly lifted revenue. Excluding this loan, our base business would have also increased on a year-over-year basis. Looking ahead and with the IPO behind us, we aim to secure more of these larger transactions going forward. Moreover, our revenue per transaction increased by 48.9 percent. This was a direct result of an increase in the average loan size, which is a testament to our ability to continue to execute on our strategy, supported by a best-in-class digital platform. Our strategy remains focused around building an all-star team to execute on our key initiatives including scaling our AI, enhancing our marketplace for borrowers and lenders, and continuing to provide best-in-class educational content across our ecosystem of websites to drive our best-in-class SEO and resulting organic traffic. Our focus is delivering long-term shareholder value via delivering cost-effective value throughout our entire ecosystem to all stakeholders. Through the implementation of generative AI and our digital platform, we have maintained a lean, scalable and high gross-margin infrastructure."

07:34 EDT Cybin announces grant of U.S. patent covering deuterated tryptamines - Cybin announced that the United States Patent and Trademark Office or USPTO, has granted U.S. patent 11,746,088, covering composition of matter for deuterated tryptamine compounds and pharmaceutical compositions thereof, with exclusivity until 2041. The newly granted U.S. patent covers deuterated 5-methoxy-dimethyltryptamine analogs in the Company's pre-clinical deuterated tryptamine portfolio and further strengthens the Company's leadership position in the development of potential best-in-class deuterated tryptamine-based therapeutics for the treatment of mental health conditions. "The grant of this patent is timely as we recently entered into a definitive agreement to acquire Small Pharma Inc., a leading developer of short-duration psychedelic therapeutics, together creating the psychedelic sector's most impressive and robust intellectual property portfolio. The strong synergy of our collective intellectual property provides an unparalleled opportunity to develop novel, differentiated therapeutics for patients in need of improved treatment options," said Doug Drysdale, Chief Executive Officer of Cybin. "Looking towards the next chapter for the combined company, this new composition of matter patent will have an important role in protecting the continued advancement of our development pipeline."

07:32 EDT First Advantage acquires Infinite ID for $41M - First Advantage announced the acquisition of Infinite ID, a U.S.-based digital identity authentication solutions company and portfolio company of Enlightenment Capital. The $41 million all-cash transaction was funded with cash from the balance sheet and expands First Advantage's network and portfolio of identity solutions in the United States. Infinite ID is profitable and is expected to generate annual revenues of over $10 million.

07:31 EDT Peraso releases PRM2144X mmWave module - Peraso announced the release of the PRM2144X , Peraso's latest mmWave module in the Company's PERSPECTUS series featuring long range, outdoor applications. Utilizing the Peraso X720 60 GHz chipset, the PRM2144X is designed for dense urban areas. A novel 128 element, integrated, phased array antenna, provides high gain, narrow beamwidth, and extremely low antenna side-lobes. Combined with Peraso's intelligent Media Access Control features, the PRM2144X enables wireless Internet service provider operators to deploy long range, multi-point networks without fear of interference in dense user environments. The increased gain and range also benefit sub-urban and rural deployments, eliminating the need for dish antennas in many cases.

07:29 EDT NextSource Materials enters MoU for POSCO collaboration - NextSource Materials announced the signing of a non-binding Memorandum of Understanding with South Korea's POSCO International for strategic collaboration that could involve an equity investment into the Company as well as a long-term offtake agreement for spheronized and purified graphite and the Company's other graphite products. The MoU envisages the potential for a definitive offtake agreement for 30,000 tonnes per annum of SuperFlake graphite concentrate and 10,000 to 15,000 tpa of SPG over a ten year period, to be supplied to POSCO Future M, a POSCO Group subsidiary that is responsible for EV battery businesses and supplies all of South Korea's major battery cell manufacturers with finished cathode and anode materials. Prior to executing a definitive agreement, certain customary technical and economic studies will need to be completed.

07:26 EDT BioCryst reports inducement grants under Nasdaq listing rule - BioCryst Pharmaceuticals granted five newly-hired employees stock options to purchase an aggregate of 28,300 shares, and restricted stock units covering an aggregate of 19,900 shares, of BioCryst common stock. The options and RSUs were granted as of August 31, 2023, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $7.11 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst's Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.

07:24 EDT BioCardia reports interim efficacy results in Phase 3 CardiAMP Cell Therapy - BioCardia has finalized external review of interim data and evaluated interim efficacy results for the ongoing Phase III pivotal trial of CardiAMP Cell Therapy for Heart Failure for which the FDA granted Breakthrough Designation for the treatment of heart failure of reduced ejection fraction, or HFrEF. The external review both confirmed the quality and appropriateness of the work by the Statistical Data Analysis Center at the University of Wisconsin and the DSMB in their review and recommendation. The interim efficacy review by the DSMB did not include the final results of the study but is an analysis of the data as part of the adaptive statistical analysis plan. For the first-tier, all cause death, including cardiac death equivalents, there were 5.6% of CardiAMP treatment patients versus 5.3% for the control group. All available follow-up in the patients followed up to 24 months showed a separation between groups with 8.3% all cause death including cardiac death equivalents in the treatment group versus 13.2% in the control group , corresponding to a 37% relative risk reduction for Tier 1 events for the treated patients compared to control patients on guideline directed medical therapy. For the second-tier, non-fatal major adverse cardiac events, 16.7% of treatment group had MACCE compared to 15.8% of the control group. Based on these measures at one year follow-up, the 250-patient randomized controlled study is unlikely to meet its primary three-tiered FS efficacy endpoint. This interim randomized study data does not include the study's roll-in open label cohort of 10 patients treated who did well with 100% survival at two-year follow-up.

07:22 EDT Enthusiast Gaming president Bill Karamouzis resigns - Enthusiast Gaming Holdings announced that Bill Karamouzis has tendered his resignation as President to pursue other professional endeavors, effective immediately. He will continue to serve the Company as an advisor.

07:20 EDT Mobilicom to trade exclusively on Nasdaq - Mobilicom shares will trade exclusively on the Nasdaq Capital Market following the voluntarily delisting of its ordinary shares from trading on the Australian Securities Exchange. Under Australian law and ASX rules, the delisting of Mobilicom's ordinary shares from trading on the ASX will take place at least 30 days after the date of this announcement, which is expected to be on or about October 11, 2023. Mobilicom will announce the exact date of its ASX delisting when it becomes available. Mobilicom's American Depositary Shares, each of which represents 275 ordinary shares, will continue to trade on the Nasdaq Capital Market under the symbol "MOB" without interruption.

07:19 EDT Yara announces findings from mineral fertilizer long-term trial - The long-term trial was conducted at Yara International's Hanninghof research center in Dulmen, Germany, and studied the long-term effects of nutrient management in farming. The study concludes that balanced application of mineral fertilizer is part of sustainable crop production, with minimal environmental impact. Established in 1958, the LTT portrays the pivotal role of balanced nutrition in soil health maintenance. The research findings address the challenges facing the global food system, and the increasingly urgent need for effective resource management to ensure a resilient food system while protecting the environment. The relationship between nutrient application and soil fertility is best studied in LTTs because soil fertility develops gradually. Therefore, evaluating its effect on crop production requires monitoring over a long time and proper data documentation. It can take decades before changes become visible, for example, trends of crop yield and effects of the environment on agriculture or vice versa. Since agriculture is removing nutrients from the soil with each harvest, an efficient replacement of nutrients back into the soil is required to sustain crop yields. While an unbalanced application of nutrients results in low nutrient use efficiency and high environmental pollution, the Hanninghof study concludes that the best solution to achieve both effective and sustainable agriculture is a balanced combination of mineral nutrients and integration of organic fertilizer available on the farm with mineral fertilizer. Key findings from Hanninghof LTT Increased soil health: Application of mineral and organic fertilizers increased soil organic carbon compared to the treatments without any fertilizer. This was also observed in many long-term studies around the globe; e.g., in Magruder LTT at Oklahoma, Aula et al. reported a significant increase in soil organic carbon content through the application of either nitrogen and phosphorus, or nitrogen, phosphorus and potassium combined compared to plots without any fertilizer. Increased water use efficiency: The use of nitrogen, phosphorus, potassium and magnesium fertilizer resulted in the highest water use efficiency compared to omitting nutrients or using just manure alone. Omitting nutrients decreased water use efficiency by up to 63%. Improved profitability: Application of the mineral nutrients; nitrogen, phosphorus, potassium and magnesium fertilizers as a balanced nutrition resulted in the highest yield and income of crop. Omitting nutrients reduced crop yield and resulted in an economic loss of between 89 and 812 USD per hectare

07:18 EDT EnCore Energy provides update on South Texas Alta Mesa ISR plant, wellfield - enCore Energy provides an update from the South Texas Alta Mesa In-Situ Recovery, ISR, Uranium Central Processing Plant and Wellfield. Upgrades and refurbishments continue to advance as planned and on schedule for the 2024 resumption of uranium production. The Company also announces further positive results from the wellfield delineation drill program and a continuing advancement of the newly discovered mineralized zone at the Alta Mesa wellfield. Site and production resumption work at the Rosita ISR Uranium Central Processing Plant and Wellfield also remains on schedule for 2023 production. The Alta Mesa ISR Uranium Central Processing Plant is advancing towards a restart of production and presently completing minor scheduled renovations with equipment upgrades and refurbishments underway. Paul Goranson, enCore's Chief Executive Officer added "The enCore operations team has made steady progress in restoring the Alta Mesa CPP towards a 2024 restart of production while also installing the Production Authorization Area wellfield. enCore's management team has dealt with similar start-up challenges in the past, and we have been very realistic about anticipated cost increases and challenging workforce recruitment. We have been strategic in our efforts to recruit skilled management and operators with previous experience at the Alta Mesa CPP and Wellfield. Our strategy also included building a skilled team to successfully expand our activities across our portfolio of ISR uranium projects."

07:16 EDT Insmed announces results from its Phase 3 ARISE study of ARIKAYCE - Insmed announced positive topline results from its Phase 3 ARISE study of ARIKAYCE in patients with newly diagnosed or recurrent nontuberculous mycobacterial, NTM, lung infection caused by Mycobacterium avium complex, MAC, who had not started antibiotics. The study met its primary objective of demonstrating that the Quality of Life - Bronchiectasis respiratory domain works effectively as a patient-reported outcome instrument in patients with MAC lung disease. Based on these results, Insmed plans to propose to the U.S. Food and Drug Administration that the QOL-B respiratory domain PRO be the primary endpoint for the ENCORE study without any modifications. Patients in ARISE were randomized 1:1 to treatment with ARIKAYCE plus macrolide-based background regimen or placebo plus macrolide-based background regimen for six months, followed by one month off treatment. ARIKAYCE-treated patients performed better than those in the comparator arm as measured by the QOL-B instrument, with 43.8% of patients achieving an improvement in QOL-B respiratory score above the estimated meaningful within-subject score difference of 14.8, compared with 33.3% of patients in the comparator arm. While the study was not powered to show a statistically significant difference between treatment arms, a strong trend toward significance was observed for improvement from baseline at Month 7. Patients in the ARIKAYCE arm also achieved nominally statistically significantly higher culture conversion rates at Month 7 versus patients in the comparator arm, and culture conversion was faster and more likely to persist through Month 7 for the ARIKAYCE arm. Based on the results of ARISE, Insmed plans to explore with global regulators accelerating the filing for approval of ARIKAYCE in newly infected patients with MAC lung disease. In parallel, the Company continues to enroll patients in ENCORE, which will use the PRO tool that has been validated in ARISE, with 250 patients expected to be enrolled by the end of 2023. Enrollment in ENCORE is expected to continue into 2024 to ensure a high degree of statistical powering and Insmed anticipates reporting topline data from ENCORE in 2025.

07:15 EDT UMH Properties provides 2023 operations update - UMH Properties is providing investors with an update on our third quarter 2023 operating results. Demand throughout our portfolio remains strong as evidenced by our monthly rent roll and occupancy growth. For the first two months of the third quarter, approximately 234 rental homes in inventory were occupied, making them income producing, and 25 new homes were sold, creating additional site rent. This resulted in an increase in overall occupancy of approximately 167 units. Year-to-date, approximately 845 rental homes in inventory were rented, making them income producing, and 108 new homes were sold. This increase in occupancy, together with rent increases implemented throughout the year, generated an increase in monthly rental charges of approximately $243,000 as of September 1, 2023, compared to August 1, 2023. For the first two months of the quarter, monthly rental charges increased by $377,000. Year-to-date, monthly rental charges have increased by $1.2 million. At the start of this year, our inventory was over 1,000 homes and has been substantially reduced over the last eight months. Our current inventory is approximately 488 homes, which is still above our normal levels, but is continuing to rapidly decrease as we continue to fill over 100 homes a month. This reduction in inventory has resulted in a decrease in our floor plan loan balance, resulting in a decrease in our floor plan interest expense.

07:15 EDT Daqo New Energy provides update on $700M share repurchase program - Daqo New Energy provided an update on its USD$700 million share repurchase program that was announced on November 7, 2022. As of today, approximately 43.1% of the authorized repurchase amount under the program has been executed through repurchases by an intermediary in the open market at prevailing prices or in privately negotiated transactions. The Company has repurchased 7.28 million ADSs for approximately $301.7 million under the current program, at an average cost of $41.42 per ADS. Xiang Xu, Chairman and CEO of the Company, commented, "In the month of August, we accelerated our pace, repurchasing 3.11 million ADSs for approximately $112.9 million, at an average cost of $36.22 per ADS. We believe that our shares are undervalued despite our solid performance and our industry's promising outlook. As a result, we expect to continue to buy back ADSs when they are trading below our expectations. The Company's balance sheet and liquidity positions are robust. At the end of the second quarter, the Company had a cash balance of $3.2 billion and a combined cash and bank note receivable balance of $4.0 billion. In the first half of 2023, the Company had an operating cash inflow of $786 million. Hence, the upper limit of our share repurchase program remains unchanged at $700 million, and we are committed to executing the program through the remainder of 2023. The timing of repurchase, number of shares repurchased and prices paid will depend upon the Company's business developments and market conditions, as well as corporate governance and regulatory restrictions, including any blackout period requirements."

07:14 EDT Green Thumb Industries board approves $50M share repurchase program - Green Thumb Industries Board of Directors has authorized the repurchase pursuant to a normal course issuer bid, of up to 10,486,951 of its Subordinate Voting Shares from time to time over a 12-month period. The Board of Directors authorized the Company to spend up to $50 million for the repurchase program.

07:13 EDT Wishpond announces partnership with Fiverr Certified - Wishpond Technologies (WPNDF) announces a partnership with Fiverr International (FVRR). Wishpond's partnership with Fiverr leverages 'Fiverr Certified' recently launched as part of Fiverr Business Solutions, where Fiverr will build a freelance marketplace for its tech partners. The Fiverr Certified team will selectively scout skilled professionals and agencies, both internally and from Wishpond's existing partner network. "We are thrilled to be collaborating with Fiverr to create a marketplace where our customers can access expert services and solutions from vetted, certified professionals," said Ali Tajskandar, Chairman and CEO of Wishpond. "We believe that partnering with Fiverr Certified unlocks a new client segment for us which we haven't been able to reach before and we're excited to be able to offer new solutions to ensure our customers get the most out of our platform."

07:12 EDT Invivyd appoints William Duke as CFO - Invivyd announced the appointment of William Duke as CFO. Mr. Duke will lead Invivyd's financial strategy to support the company's continued growth. Prior to joining Invivyd, Mr. Duke served as the CFO of Apexigen.

07:11 EDT AxoGen announces full launch of Axoguard HA+ Nerve Protector - Axogen announced the full launch of Axoguard HA+ Nerve Protector, a proprietary nerve protection device designed to provide both short- and long-term protection for peripheral nerve injuries. The device is comprised of a processed porcine submucosa extracellular matrix base layer with a hyaluronate-alginate gel coating. The gel layer facilitates enhanced nerve gliding to aid in minimizing soft tissue attachments, while the base layer is remodeled into a long-term protective tissue layer. The nerve protection category covers a wide range of injuries and defects, including nerve compression, crush, and complex traumatic injuries.

07:10 EDT Autolus Therapeutics announces data from AUTO1/22 trial - Autolus Therapeutics announces a publication on the AUTO1/22 Phase 1 study in Pediatric B-cell Acute Lymphoblastic Leukemia in the journal Blood,1 previously presented this year at the European Society for Blood and Marrow Transplantation in April. CD19 negative relapse is a major cause of treatment failure after CD19 CAR T cell therapy for pediatric B-ALL. To address this, AUTO1/22 is designed to target both CD19 and CD22 using the fast-off rate CD19 CAR from obecabtagene autoleucel combined with a novel CD22 CAR capable of effective signaling in response to low antigen density/ Twelve patients with advanced pediatric B-ALL were treated. Patients on study were high risk, with 4 patients who had failed prior CD19 CAR therapy, 3 patients with a CD19-negative disease component, 3 patients with non-CNS extramedullary disease and 6 patients who had received prior blinatumomab. AUTO1/22 maintained the safety profile of obe-cel alone, with no cases of severe cytokine release syndrome. AUTO1/22 induced MRD-negative CR in 83% patients. This includes 2 patients who had CD19 negative disease, demonstrating the efficacy of the CD22 CAR. Two patients failed to respond: one with CD19+/CD22+ disease and another with progression of double CD19-/CD22- disease, present as a minor leukemic cell population pre-infusion. Of 10 responding patients, 5 had emergence of MRD or frank relapse with CD19 and CD22 expressing disease associated with loss of CAR T-cell persistence. Importantly, there were no cases of relapse due to antigen-negative escape, with a median follow-up of 8.7 months. Overall survival was 75% at 6 and 12 months. Six and 12-month event free survival were 75% and 60% respectively.

07:09 EDT Helius Medical regains compliance with Nasdaq listing rules - Helius Medical received formal notice from Nasdaq indicating that Helius has evidenced full compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a) and otherwise satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result, the listing matter has been closed.

07:08 EDT Stoke presents data for STK-001 development to treat Dravet Syndrome at IEC - Stoke Therapeutics announced highlights from presentations related to the ongoing clinical development of STK-001, the first potential new medicine to treat the underlying cause of Dravet syndrome. Four posters from the Company's work in Dravet syndrome are being presented at the International Epilepsy Congress IEC 2023, September 2-6, in Dublin, Ireland. Data from the recently announced analysis of results from the ongoing Phase 1/2a studies MONARCH & ADMIRAL and the SWALLOWTAIL open-label extension study are being presented in a scientific forum for the first time. In addition, a new pharmacokinetic PK analysis of 61 patients treated in STK-001 clinical trials is being presented for the first time, and demonstrates a correlation between higher STK-001 drug exposure in brain and greater reductions in seizure frequency over time. "The data from ongoing studies of STK-001 provide the first evidence of a disease modifying medicine for Dravet syndrome," said Helen Cross, MB ChB, Ph.D., Professor, The Prince of Wales's Chair of Childhood Epilepsy and Director of University College London Great Ormond Street Institute of Child Health, Honorary Consultant in Paediatric Neurology, and the ADMIRAL study lead investigator. "The primary goal of these studies is to assess safety and tolerability as well as to inform dose selection for future studies. Importantly, within these data we can now see a differentiated pattern of response emerging among the 11 patients treated with an initial two or three doses of 70mg. Additionally, data from the open-label extension study that is evaluating ongoing dosing at lower levels showed, for the first time, improvements in multiple measures of cognition and behavior among patients who have been highly refractory to standard anti-seizure medicines." The potential of STK-001, a proprietary antisense oligonucleotide ASO , to be the first disease-modifying medicine for Dravet syndrome is supported by multiple presentations of clinical and other data at IEC.

07:08 EDT Krystal Biotech's KB408 granted Orpah Drug Designation in AATD - Krystal Biotech announced that the FDA granted Orphan Drug Designation for KB408 for the treatment of alpha-1 antitrypsin deficiency, or AATD. AATD is caused by mutations in the SERPINA1 gene that lead to decreased levels and/or decreased functionality of alpha-1 antitrypsin protein. Over time, the deficiency can lead to progressive enzymatic destruction of the lung tissue, ultimately causing life-threatening pulmonary impairment and severe respiratory insufficiency. In severe cases, current disease management includes intravenous augmentation therapy which requires weekly infusions, the clinical benefit of which remains to be established. KB408 is an inhaled formulation of the company's replication-defective, non-integrating HSV-1-based vector designed to deliver two copies of the SERPINA1 transgene, that encodes for human alpha-1 antitrypsin protein, for the treatment of AATD.

07:06 EDT First Mining Gold announces initial results from Duparquet Gold Project - First Mining Gold announces the confirmation of a new gold zone based on initial results from its Phase I exploration drilling program at the Duparquet Gold Project located in Quebec, Canada. "These first drill holes have now confirmed a new modeled gold zone at the Duparquet Gold Project," stated Dan Wilton, CEO of First Mining. "With further drilling to continue, First Mining is well positioned to continue advancing this strategically important project located in the prolific Abitibi Greenstone Belt. The ongoing drilling success at Duparquet will provide upside potential to the Duparquet Gold Project where First Mining is currently advancing on a PEA and expect to have that completed in Q3 2023."

07:05 EDT Brady board authorizes additional $100M share repurchase - On August 30, 2023, Brady's Board of Directors authorized an additional $100 million of Class A Common Stock for repurchase under the Company's share buyback program. The share buyback plan may be implemented from time to time in the open market or in privately negotiated transactions and has no expiration date.

07:03 EDT Xylem CEO Patrick Decker to retire, Matthew Pine to succeed - Xylem announced that after a distinguished decade leading Xylem, President and CEO Patrick Decker has announced his plans to retire as CEO at the end of 2023. In accordance with the Company's long-term succession planning process, Decker will be succeeded by Matthew Pine, Xylem's COO, effective January 1, 2024. At that time, Decker will retire from Xylem's Board and Pine will join as a Director. Decker and Pine will work closely together to ensure a smooth transition. Xylem has also appointed William Grogan, formerly CFO of IDEX Corporation, to Senior Vice President and CFO, effective October 1, 2023. Grogan succeeds Sandra Rowland who is leaving to pursue new and different opportunities. Both Decker and Rowland will remain employed through March 2024 to serve as advisors and support the transitions.

07:02 EDT Opal Fuels announces $500M credit facility - OPAL Fuels announced the closing of a new $500 million senior secured credit facility. The Credit Facility consolidates certain existing indebtedness and provides approximately $300 million in availability, which is anticipated to be used principally for development and construction of renewable energy projects. Apterra Infrastructure Capital LLC functioned as Sole Bookrunner and Syndication Agent for the Credit Facility and Bank of America, N.A. is Administrative Agent.

06:51 EDT Perfect Corp. announces updates to AI-Powered Live Skin Analysis Solution - Perfect Corp. announced updates to its AI-Powered Live Skin Analysis Solution. The HIPAA-compliant and dermatologist-verified technology empowers users to gain deep insights into their skin condition and receive personalized skincare recommendations, while an AR overlay highlights specific skin concerns in real-time. The new functionality of the AI Skin Analysis innovation analyzes up to 14 skin concerns through live camera mode, enabling users to view real-time detections of various areas around their face.

06:37 EDT Rapid7 announces proposed privated offering of $250M of senior notes - Rapid7 intends to offer, subject to market conditions and other factors, $250 million aggregate principal amount of convertible senior notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Rapid7 also intends to grant the initial purchasers of the notes an option to purchase up to an additional $37.5 million aggregate principal amount of notes. The notes will be general unsecured obligations of Rapid7 and will accrue interest payable semiannually in arrears. The notes will be convertible into cash, shares of Rapid7's common stock or a combination of cash and shares of Rapid7's common stock, at Rapid7's election. The interest rate, initial conversion rate and other terms of the notes will be determined at the time of pricing of the offering. Rapid7 expects to use a portion of the net proceeds from the offering of the notes to repurchase a portion of its outstanding 2.25% Convertible Senior Notes due 2025 in one or more separate and privately negotiated transactions expected to be entered into concurrently with the pricing of the offering and to pay the cost of the capped call transactions described below. The terms of any repurchases of the 2025 notes are anticipated to be individually negotiated and will depend on several factors, including the market price of Rapid7's common stock and the trading price of the 2025 notes at the time of such repurchases. Rapid7 expects to use the remainder of the net proceeds for general corporate purposes, which may include continued investment in its sales and marketing efforts, product development, general and administrative matters, and working capital. Rapid7 may also use a portion of the proceeds from this offering for acquisitions or strategic investments in complementary businesses or technologies, although it does not currently have any plans for any such acquisitions or investments.

06:35 EDT Probe Metals files NI 43-101 technical report for Novador Project - Probe Gold announced that following the release of an updated Mineral Resource Update on July 19th, 2023, the Company has filed a National instrument 43-101 Technical Report for Novador Project entitled, "NI 43-101 Technical Report and Updated Mineral Resource Estimate for the Novador Project, Quebec", prepared by InnovExplo Inc, dated September 1st, 2023, with an effective date of July 13, 2023. Highlights: Total Val-d'Or properties gold mineral resources currently stand at 3,793,900 ounces Measured and Indicated and 1,418,700 ounces Inferred along all trends and deposits, representing a 28% increase from the 2021 Mineral Resource Estimate. Novador Project gold mineral resources, slated for development, currently stand at 3,793,900 ounces M&I and 1,179,400 ounces Inferred along the Monique, Pascalis, and Courvan gold trends deposits, representing a 30% increase from the 2021 Mineral Resource Estimate. Other Val-d'Or properties gold mineral resources currently stand at 239,200 ounces Inferred, including the Lapaska and Sleepy deposits. Significant mineral resources growth observed at the Monique deposit and strong conversion to M&I mineral resources seen at all three, Monique, Pascalis and Courvan gold trends deposits. Increases of 28% in total ounces and 72% of ounces contained in pit-constrained mineral resources, with strong potential for future resource growth. The Novador mineral resource estimate demonstrates significant increase in M&I ounces, with 111% increase in overall M&I ounces. Novador Monique and Pascalis gold trend deposits represent 83% of the pit-constrained Mineral Resource Estimate.

06:34 EDT Aspen Aerogels CHRO Kelley Conte to retire, Stephanie Pittman to succeed - Aspen Aerogels announced the appointment of Stephanie Pittman as chief human resources officer. Pittman will report to Don Young, Aspen's president and CEO, joining the company's executive committee. Pittman will succeed Kelley Conte, senior VP of human resources, who will retire from Aspen following an tenure as a Aspen leader over the last eight years. She previously served as the executive VP and chief human resources officer at Excelitas Technologies.

06:33 EDT Freight Technologies reports capacity levels from Fr8Fleet - Freight Technologies reports a record number of active carriers in its Fr8Fleet brand at end of August 2023, an increase of 60.8% versus year-ago levels and an increase of 55.7% versus YTD average capacity levels through August. "Following a challenging first quarter of the year, we had to cycle through some underperforming carriers during Q1-23 - which hurt our numbers for the first quarter, but we believe we did the right thing to maintain the expected high level of quality of our service, and we are getting back on track," said Luisa Lopez, COO for Fr8Tech. "The additional carrier capacity is something we are actively working to address - not only during the first quarter but for a number of months to come. An important limitation to our ability to grow the Fr8Fleet brand has been related to securing high-quality carrier capacity, and we have focused on doing just that for some time, and our efforts are starting to bear fruit. We expect to be able to show improvements in recurring monthly revenue from Fr8Fleet through the remainder of the calendar year and into 2024. In the Mexico domestic market, we have confirmations of existing shipper clients for our Fr8Fleet business to continue growing through the balance of 2023. We have been tirelessly working on getting these key large shipper clients on our platform, and we are pleased to announce the corresponding increase in carrier activity on our platform. We need both sides of the platform to make a marketplace, and we continue working toward creating critical mass on both the demand and supply sides of our platform. Our capacity for this segment is up year over year and we have had steady monthly increases since February 2023 which will start showing up in our results for both this upcoming third quarter and the ones to follow."

06:22 EDT Freyr Battery welcomes SAP to Energy Transition Acceleration Coalition - FREYR Battery (FREY) has announced that SAP (SAP) has joined FREYR's Energy Transition Acceleration Coalition. With the addition of SAP, the ETAC, which is a collaborative alliance of global business partners focused on commercializing decarbonization solutions through clean battery deployment, now includes Glencore (GLNCY), Caterpillar (CAT), Siemen (SIEGY), and Nidec Corporation (NJDCY).

06:18 EDT Trivago no longer expects 2023 adjusted EBITDA to exceed EUR70M - As part of a multi-year strategy to rejuvenate its brand presence, the company aims for a return to double-digit revenue growth in the medium term.

06:17 EDT KLA Corp. increases quarterly dividend to $1.45 per share - KLA Corp. announced an increase in the quarterly dividend level to $1.45 per share from $1.30 per share, the fourteenth consecutive annual increase in the quarterly dividend level for KLA. The declaration and payment of future dividends is subject to the board's discretion and will depend on financial and legal requirements and other considerations. The company is also announcing authorization from the board of directors to repurchase up to $2B of the company's common stock. This is in addition to the existing share repurchase authorization, which had approximately $1.6B remaining as of Aug. 31, 2023.

06:14 EDT Quantum Computing enters sales, teaming agreement with Assured Cyber Protection - Quantum Computing announced the signing of a strategic sales and teaming agreement with AI-empowered cybersecurity assessment, continuous detection, and mitigation company, Assured Cyber Protection. The key objective of the strategic sales and teaming agreement between QCi and Recyber is to coordinate efforts to market and deliver both companies' proprietary cyber security technologies and products.

06:13 EDT 1847 Holdings receives deficiency letter from NYSE American - 1847 Holdings received a deficiency letter from NYSE American on August 31, 2023 stating that the Company is not in compliance with the continued listing standards as set forth in Section 1003(f)(v) of the NYSE American Company Guide/ The Letter stated that because the Company's common shares had been trading for a low price per share for a substantial period of time, which NYSE American determined to be a 30-trading day average of less than $0.20 per share. The Company was not in compliance with Section 1003(f)(v) of the Company Guide. The NYSE American staff determined that the Company's continued listing is predicated on it demonstrating sustained price improvement within a reasonable period of time or effecting a reverse stock split of its securities, which the staff determined to be until February 29, 2024. The Letter also noted that NYSE American may take an accelerated delisting action that would pre-empt the cure period in the event that the common stock trades at a level viewed to be abnormally low. The Letter has no immediate effect on the listing or trading of the Company's common shares and the common shares will continue to trade on the NYSE American under the symbol "EFSH". The Company's receipt of the Letter does not affect the Company's business, operations or reporting requirements with the Securities and Exchange Commission. As previously disclosed on September 1, 2023, through a press release, in order to resolve the deficiency the Company will effect a 1-for-25 reverse stock split of its common shares that will become effective on September 11, 2023. The Company's common shares will continue to trade on NYSE American under the symbol "EFSH" and will begin trading on a split-adjusted basis when the market opens on September 11, 2203. The new CUSIP number for the common shares following the reverse split will be 28252B887. The Company's board took the action to implement the reverse split only after it received written notification from the NYSE American on August 31, 2023. The Company is a limited liability company, and under Delaware Law and the Company's operating agreement, the board is authorized to effect a reverse stock split without shareholder approval or the need to make any filing in the state of Delaware. Out of an abundance of caution and what the Company believes to be in the best long-term interests of shareholders, the Board of Directors approved the reverse split on August 31, 2023, which it believes will allow the Company to regain compliance with the minimum bid price requirement.

06:09 EDT Bristol Myers, Zenas BioPharma enter strategic license, collaboration agreement - Zenas BioPharma has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialize obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia. Obexelimab is an investigational bifunctional, non-cytolytic, humanized monoclonal antibody that binds CD19 and FcgammaRIIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells. Obexelimab is currently being studied as a subcutaneous injection in a global Phase III trial in patients with IgG4-Related Disease, a disease for which there are currently no approved treatments. The compound is also being studied in a global Phase II/III trial in patients with warm antibody Auto-Immune Hemolytic Anemia. Under the terms of the license agreement, Zenas will receive a $50 million up-front cash payment and is eligible to receive additional payments in connection with the achievement of certain development, regulatory and commercial milestones, as well as royalties on net sales of obexelimab in the licensed territory. In exchange, Bristol Myers Squibb will receive exclusive rights to develop and commercialize obexelimab in the licensed territory. In addition, Bristol Myers Squibb is making an equity investment in Zenas.

06:04 EDT Brunswick acquires Fliteboard - Brunswick acquired Fliteboard, a provider of eFoiling technology, that will enhance the company's electrification and shared-access strategies. Fliteboard, which combines advanced hydrofoils and electric propulsion on the water, allows Brunswick to enter the emerging, electric-foiling surfboard market. Fliteboard will operate as a business within Mercury Marine. Fliteboard, established in 2016, has customers in more than 90 countries.

06:02 EDT Ensign Group acquires two skilled nursing facilities in South Carolina - Ensign Group acquired the operations of Ashley River Healthcare, a 125-bed skilled nursing facility located in Charleston, South Carolina, and The Reserve Healthcare and Rehabilitation, a 135-bed skilled nursing facility located in Hanahan, South Carolina. These acquisitions were effective September 1 and will be subject to a long-term, triple net lease. These acquisitions bring Ensign's portfolio to 295 healthcare operations, 26 of which also include senior living operations, across thirteen states.

05:33 EDT Arthur J. Gallagher acquires Lifesure Group, terms undisclosed - Arthur J. Gallagher announced the acquisition of UK-based Lifesure Group Limited. Terms of the transaction were not disclosed. Lifesure provides personal lines insurance broking services in the vacation/holiday and leisure industry, with products including park home, motorhome, caravan and leisure home insurance. As part of the transaction Gallagher will also acquire Lifesure's affiliated company Barnes Commercial, an insurance broker serving small-to-medium businesses. Paul Reid and his team will become part of Gallagher's UK & Ireland Retail division.

05:22 EDT Addex Therapeutics announces ADX71149 study readout expected in 2Q24 - Addex Therapeutics (ADXN) announced that the ADX71149 Phase 2 epilepsy clinical study is progressing with Cohort 1 completed and 80% of patients recruited into Cohort 2. Results evaluating the efficacy, safety and tolerability of ADX71149 in combination with levetiracetam or brivaracetam from patient Cohorts 1 and Cohort 2 are anticipated for the second quarter of 2024. The primary efficacy endpoint of this study is time to baseline monthly seizure count. Collaboration partner Janssen Pharmaceuticals of Johnson & Johnson (JNJ), is responsible for the clinical development of ADX71149. As previously announced on May 10, an independent Interim Review Committee, or IRC, convened by our collaboration partner recommended to continue the study following review of unblinded data from Part 1 of patient Cohort 1.

05:15 EDT Mainz Biomed enters pact with Arztliches Labor Dr. Buhlmann in Germany - Mainz Biomed announced a strategic partnership with Arztliches Labor Dr. Buhlmann, a move aimed at further strengthening its position in the German market. The collaboration grants Mainz Biomed greater access to, and the potential for further expansion into Germany's private health insurance segment where ColoAlert, its detection test for colorectal cancer, or CRC, already receives reimbursement.

05:10 EDT Sinovac board unanimously rejects partial tender offer by Alternative Liquidity - Sinovac Biotech announced that its board of directors unanimously determined that the partial tender offer by Alternative Liquidity Index to acquire up to 10M common shares of Sinovac for 3c per share in cash is not advisable and is not in the best interests of the company or its shareholders. Accordingly, the board of directors recommends that the shareholders reject the tender offer and not tender their shares for purchase pursuant to the offer to purchase by Alternative Liquidity.